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Abstract 14 
The increasing use of illegal drugs by pregnant women causes a public health concern because 15 
it is associated with health risks for mothers and their developing children. One of such drugs is 16 
MDMA (3,4-methylenedioxymethamphetamine) or ecstasy due to its high consumption in 17 
relevant age and sex groups and its adverse effects on human and rodent developing brains. To 18 
thoroughly review the current knowledge on the developmentally neurotoxic potential of 19 
MDMA we systematically collected and summarized articles investigating developmental 20 
neurotoxicity (DNT) of MDMA in humans and animals in in vivo and in vitro. In addition, we 21 
summarized the findings in a putative adverse outcome pathway (AOP). From an initial 299 22 
articles retrieved from the bibliographic databases Web of Science, PubMed and DART, we 23 
selected 39 articles according to inclusion/exclusion criteria for data collection after 24 
title/abstract and full text screening. Of these 3 where epidemiological studies, 34 where in vivo 25 
studies in mice and rats and 2 were in vitro studies. The three epidemiological studies reported 26 
from the same longitudinal study and suggested that MDMA exposure during pregnancy impairs 27 
neuromotor function in infants. In rat, postnatal exposure towards MDMA also caused 28 
locomotor deficits as well as impaired spatial learning that might be associated with decreased 29 
serotonin levels in the hippocampus. In vitro MDMA caused cytotoxicity at high concentrations 30 
and effects on the serotonergic and neuritogenic alterations at lower concentrations which are 31 
in line with some of the in vivo alterations observed. Considering the adverse outcomes of 32 
developmental MDMA described in humans and in rodents we summarized the first putative 33 
AOP on developmental compound exposure leading to impaired neuromotor function in 34 
children. For generation of this AOP, MDMA exposure was taken as a model compound. In 35 
addition, we hypothesized a second AOP involving developmental disturbance of the 36 
dopaminergic system. However, further in vitro mechanistic studies are needed to understand 37 
the molecular initiating event(s) (MIE) triggering the downstream cascades and obtain 38 
consistent evidences causally linking the adverse outcome to effects at the cellular, organ and 39 
organism level. 40 
Keywords: neurodevelopment; amphetamine derivative; pregnancy; AOP; motor function; 41 
epidemiological ToxRTool. 42 
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Abbreviation list 43 
5-HIAA: 5-Hydroxyindoleacetic acid 44 
5HT: serotonin 45 
AIMS: Alberta Infant Motor Scales 46 
AO: adverse outcome 47 
AOP: adverse outcome pathway 48 
BDNF: brain-derived neurotrophic factor 49 
BRS: Behavioural Rating Scale  50 
CWRU: Case Western Reserve University 51 
DA: dopamine 52 
DAISY: Drugs and Infancy Study 53 
DART: developmental and reproductive 54 
toxicology database 55 
DBH: dopamine beta-hydroxylase 56 
DG: dentate gyrus 57 
DIV: days in vitro 58 
DNT: developmental neurotoxicity 59 
DOPAC: 3,4-dihydroxyphenylacetic acid 60 
e.o.d.: every other day 61 
EB: embryoid bodies 62 
ECVAM: European Centre for the 63 
Validation of Alternative Methods 64 
GABA: gamma-aminobutyric acid 65 
GD: gestational day 66 
h a.i.: hours after injection 67 
hiPSC: human induced pluripotent stem 68 
cell 69 
HVA: homovanillic acid 70 
i.p.: intraperitoneal 71 
ICC: immunocytochemistry 72 
IHC: immunohistochemistry 73 
KE: key event 74 
KEGG: Kyoto Encyclopedia of Genes and 75 
Genomes 76 
KER: KE relationship 77 
LOAEC: Lowest observed adverse effect 78 
concentration 79 
LOAEL: Lowest observed adverse effect 80 
level 81 
LSD: lysergic acid diethylamide 82 
MADAM: N,N-dimethyl-2-(2-amino-4-83 
methylphenylthio) benzylamine 84 
MAP2: microtubule-associated protein 2 85 
MDI: Mental Development Index 86 
MDMA: 3,4-87 
methylenedioxymethamphetamine 88 
mESC: mouse embryonic stem cells 89 
MHPG: 3-methoxy-4-hydroxyphenylglycol 90 
MIE: molecular initiating event 91 
MoA: mode-of-action 92 
MWM: Morris Water Maze 93 
NE: norepinephrine 94 
NET: norepinephrine transporter 95 
NGF: nerve growth factor 96 
NMDAR: N-methyl-D-aspartate receptor 97 
NNNS: NICU Network Neurobehavioural 98 
Scale 99 
NT-3: neurotrophin-3 100 
o.g.: oral gavage 101 
PCPA: p-chlorophenylalanine 102 
PDI: Psychomotor Index 103 
PN month: postnatal month 104 
PND: postnatal day 105 
PPI: prepulse inhibition 106 
s.c.: subcutaneous 107 
S.D.: Sprague-Dawley 108 
TH+: tyrosine hydroxylase 109 
UEL: University of East London 110 










1. INTRODUCTION 119 
 120 
The period of highest risk for women to develop a substance use disorder overlaps with the 121 
childbearing age (18-44), especially between the ages 18 and 29 (Compton et al., 2007; Forray, 122 
2016). Furthermore, the percentage of pregnant women using illicit drugs has been increasing 123 
over the last years. According to the National Surveys on Drug Use and Health of the United 124 
States, the percentage of pregnant women reporting consumption of illegal drugs in the month 125 
before the survey increased from 5.1% in 2008 to 8.5% in 2017. Indeed, when focusing on the 126 
period of highest risk aforementioned (in this case 18 - 25 years of age) illicit drug use during the 127 
month before the survey reported by pregnant women even increased to 11.0%  in 2017 128 
(Substance Abuse and Mental Health Services Administration, 2018, 2009). Similar tendencies 129 
are observed in other countries, like Canada (Petrangelo et al., 2018), yet there is a huge gap of 130 
information on drug abusing women during pregnancy (EMCDDA, 2012). This is due to 131 
difficulties in data obtention most likely related to the social stigma associated with drug use 132 
during pregnancy. 133 
Illicit drug use during pregnancy causes a public health concern because it is associated with 134 
increased health risks for the mother and the developing child. Which health adverse outcome 135 
is created largely depends on the substance consumed. For example, adverse effects related to 136 
prenatal exposure to legal drugs like alcohol are well described by lower birth rates, preterm 137 
birth or perinatal death (Bailey and Sokol, 2011) and fetal alcohol syndrome which includes 138 
intellectual disability, birth defects and characteristic dysmorphic facial features (Chudley et al., 139 
2005). However, besides the data gap in exposure assessment, there is also little known on the 140 
adverse effects on development of many of the illicit drugs. One important example with sparse 141 
data yet public concern due to high consumption in the relevant age and sex group (EMCDDA, 142 
2017) are amphetamine derivatives like MDMA (3,4-methylenedioxymethamphetamine).  143 
MDMA or ecstasy or ‘Molly’ is a synthetic drug mainly consumed by teenagers and young adults 144 
for its psychotropic actions. These include psychostimulant and ‘entactogen’ effects enhancing 145 
emotional empathy and prosocial behaviour. Related to the entactogen effects of MDMA, 146 
several authors described that ecstasy users are more likely to engage in high risk sexual 147 
behaviours including casual and unprotected  sex (Castilla et al., 1999; Mattison et al., 2001; 148 
May and Parrott, 2015; Palamar et al., 2018). MDMA users who become pregnant normally stop 149 
taking the drug after the first trimester, although some cases of prolonged consumption have 150 
also been described (Ho et al., 2001; Moore et al., 2010; Scott et al., 2010; Van et al., 1998). 151 
Studies in pregnant rats demonstrated that MDMA crosses the placental barrier and reaches the 152 
fetal brain (Campbell et al., 2006). In addition, it was inferred that with a high probability MDMA 153 
is found in breast milk considering that it is a low-molecular-weight and hydrophobic molecule 154 
with a pKa of 10.4 (Cho et al., 2008). Several independent research groups observed adverse 155 
effects of MDMA on the developing rodent brain and few epidemiological or case report studies 156 
also described developmental neurotoxicity (DNT) of MDMA in humans. This drug has therefore 157 
been included in the list of reference compounds for alternative test methods to study their DNT 158 
potential (Aschner et al., 2017). However, the extent of the potential adverse outcomes and the 159 
mode-of-action(s) (MoA) underlying these DNT effects are enigmatic. So far, a variety of studies 160 
intended to clarify if the effects of MDMA on the developing nervous system are mediated 161 
through a similar MoA than adult neurotoxicity, i.e. causing disfunction of the serotonergic 162 
system, with serotonin depletion and loss of serotonin transporter (Parrott, 2013). Some of 163 
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these studies point out that the DNT MoA might be completely different than the one for adult 164 
neurotoxicity, yet this is currently unclear. 165 
For improved risk perception and thus prevention of harm, comprehensive information is 166 
necessary that clearly links MDMA exposure of women during pregnancy to adverse 167 
neurodevelopmental outcomes in children. As a first step, the aim of this review is to collect and 168 
summarize articles published until November 2018 on DNT effects of MDMA in humans and 169 
animals in vivo as well as in vitro. From these data, hypothetical/putative adverse outcome 170 
pathways (AOP) will be summarized that highlight the main common findings and importantly, 171 
points out the existing knowledge gaps. This approach will help accelerating the acquisition of 172 
new knowledge on MDMA-induced DNT, especially information on the MoA, which is urgently 173 
needed for a deeper understandning of dose-effect relationships and thus a hazard and risk 174 
assessment based on mechanistic understanding. 175 
 176 
2. REVIEW METHODOLOGY 177 
2.1. Search Method 178 
2.1.1. Databases 179 
Literature search was performed in three databases covering different levels of specialization: 180 
1) Web of Science: a multidisciplinary database including more than 34.200 journals, plus books, 181 
proceedings, patents, and data sets on the fields of biomedical sciences, natural sciences, 182 
engineering, social sciences, and arts and humanities (WebofScience, n.d.); 2) PubMed: a 183 
biomedical database including literature from MEDLINE, life science journals, and online books 184 
(PubMed, n.d.); 3) DART (developmental and reproductive toxicology database): a specific 185 
database belonging to the TOXNET database (toxicology data network) from the U.S. National 186 
Library of Medicine and including “journal references covering teratology and other aspects of 187 
developmental and reproductive toxicology” (DART, n.d.). The information gathering procedure 188 
used in this study is summarized in Figure 1. 189 
2.1.2. Keywords 190 
Searches performed in Web of Science and PubMed included two groups of truncated keywords: 191 
keywords related with “developmental neurotoxicity/exposure” AND “names and synonyms of 192 
MDMA and MDMA HCl obtained from ChemIDPlus (ChemIDplus, n.d.)”; while the search 193 
performed in DART only included “3,4-Methylenedioxymethamphetamine” name, as this 194 
database recognized the chemical name and automatically added synonyms and CAS number 195 
retrieved from ChemidPlus. The search in DART did not include the “developmental 196 
neurotoxicity/exposure” group of keywords because this database is already selective for 197 
references related to developmental toxicology. DART search was restricted to not include 198 
PubMed results to avoid duplicates (exclusion of the default option “Include PubMed Results”). 199 
The exact syntax with all keywords used in the three searches is detailed in Supplementary 200 
Information file 1. Timespan was not limited in any of the searches. 201 
2.2. Exclusion criteria 202 
All references obtained from the three searches (Web of Sciences: 153, PubMed: 104, DART: 42) 203 
were exported to a common Mendeley library (299 references). After excluding duplicates, 211 204 
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remaining articles were further screened based on title and abstract according to the following 205 
exclusion criteria: 206 
 Secondary literature. 207 
 Combined exposure to MDMA and other drugs. 208 
 No evaluation of neurotoxic effects. 209 
 Exposure does not occur during the developmental period (defined as gestational period 210 
in human studies, as gestation and lactation up to postnatal day 21 in rodent studies, 211 
and as exposure during cell differentiation for in vitro studies). 212 
 Species different than rodents, rabbit, zebrafish, frog, primate and human. 213 
 Articles withdrawn/retracted/removed. 214 
A total of 118 articles were excluded according to these criteria leaving 93 articles for full text 215 
screening. 216 
2.3. Classification and retrieval of selected studies 217 
Selected 93 studies were classified in three groups: studies on the DNT of MDMA (1) in humans 218 
in vivo, (2) in animals in vivo, and (3) in in vitro models. 219 
Full-text copies of the references included in groups 1, 2 and 3 were obtained from the following 220 
university libraries: Heinrich-Heine-Universität Düsseldorf, Universitat de Barcelona and 221 
Sapienza University of Rome and Fondazione Santa Lucia. 222 
2.4. Information acquisition from full texts and harmonized evaluation of methodological quality 223 
Full texts of the studies (13 from group 1, 65 from group 2 and 15 from group 3) were read and 224 
respective detailed study data gathered in a working table. While reading the full-text, article 225 
quality was evaluated and categorized using the “ToxRTool” (Schneider et al., 2009) available on 226 
the ECVAM website (http://ecvam.jrc.it, section “Publications”). This publicly available tool 227 
developed in Microsoft Excel® is based on the approach of Klimisch et al., (1997) to assess the 228 
reliability of toxicological data. The tool was used to harmonize the reliability assessment within 229 
the working group. The ToxRTool consists of two different excel sheets, one for in vivo and one 230 
for in vitro data, which were used for all studies included in groups 2 and 3, respectively. The 231 
criteria for these studies are grouped in: I) Test substance identification; II) Test 232 
system/organism characterization; III) Study design description; IV) Study results 233 
documentation; V) Plausibility of study design and results.  234 
To the best of our knowledge, there is no ToxRTool available for evaluating the quality of human 235 
epidemiological studies. Therefore, we developed our own ToxRTool for these studies based on 236 
two guidelines for DNT risk assessment (Environmental Protection Agency, 1991; Travis et al., 237 
2008). Criteria extracted from these guidelines were grouped following the same five categories 238 
as of the ToxRTool for in vivo and in vitro studies. This newly developed ToxRTool is available as 239 
a Supplementary information file 2. 240 
While reading the full-text of the articles, inclusion/exclusion of studies to the review was 241 
revised based on the same six criteria presented in section 2.2 plus exclusion criteria “ToxRTool 242 
Category 3: not reliable” and single case report studies. Figure 1 summarizes the number of full-243 






Figure 1. Summary of the search and screening strategy including the number of articles obtained at every 248 
screening step and detailing the species studied in vivo or in vitro in each article. No in vitro studies based 249 
on human cells were found. 250 
 251 
3. RESULTS and DISCUSSION 252 
3.1. Neurodevelopmental effects of prenatal exposure to MDMA in humans 253 
A total of 13 human studies were identified by the systematic search. Ten of them were excluded 254 
for the following reasons: five because they were conference abstracts, one because it did not 255 
evaluate DNT, two because it was secondary literature, one because of low quality score in the 256 
ToxRTool (category 3) and one for being a single case report. The results of the three selected 257 
ones are summarized in Table 1. 258 
Limited evidence is available on the neurodevelopmental effects of prenatal exposure to MDMA 259 
in humans. To the best of our knowledge, there is only one prospective epidemiological study 260 
evaluating neurobehavioural parameters in infants from birth up to 2 years of age after 261 
intrauterine exposure to MDMA. This longitudinal study resulted in 4 publications: the first 262 
describes the profile of drug intake of the mothers and will not be discussed here as it is not the 263 
focus of the present review (Moore et al., 2010); the second monitors the neurobehavioural 264 
outcomes of the infants at 1 and 4 months of age (Singer et al., 2012a); the third one describes 265 
the behavioural outcomes at one year of age (Singer et al., 2012b); and the fourth one compares 266 
the outcomes in a longitudinal study across the children at 1, 4, 12, 18, and 24 months of age 267 
(Singer et al., 2016). The results of this study suggest that MDMA exposure during pregnancy 268 
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impairs neuromotor function in infants. Below, we describe in detail the results of this 269 
epidemiological work and provide insights in its limitations and directions to be taken in human 270 
research of prenatal exposure to MDMA.  271 
The prospective study of Singer and colleagues compared a cohort of 28 mothers who consumed 272 
MDMA during pregnancy with 68 mothers who did not. Regardless of their MDMA intake, all of 273 
them had a history of polydrug use and continued to use other substances during pregnancy. 274 
Mothers were recruited mainly through paid adverts as a part of the Case Western Reserve 275 
University (CWRU) and University of East London (UEL) Drugs and Infancy Study (DAISY) in the 276 
UK. The neurodevelopmental outcomes of the infants were monitored from birth to 2 years of 277 
age using a battery of standardized developmental scales that evaluate motor and cognitive 278 
functions (Singer et al., 2012a).  279 
The main effect observed in MDMA-exposed infants was a motor delay detected as early as 1 280 
month after birth, which persisted until 24 months of age. This effect manifested subtly at 1-281 
month of age as a trend to more lethargic behaviours and hypotonia as measured by the NICU 282 
Network Neurobehavioural Scale (NNNS). The motor delay became more evident at 4 months 283 
of age, where MDMA-exposed children showed poorer motor quality in the Motor Quality Scale 284 
of the Behavioural Rating Scale (BRS) of the Bayley Development Scales and lower performance 285 
on the Alberta Infant Motor Scales (AIMS). Both of these scales measure gross motor 286 
maturation. Particularly, MDMA-exposed infants showed less coordination and more slow and 287 
delayed movements, and notably, this effect was dose-dependent (heavier vs lighter MDMA 288 
users; Singer et al., 2012a).  289 
At 12 months of age, consistently with the early findings, MDMA-exposed children showed a 290 
lower Psychomotor Index (PDI) of the Bayley Development Scales, an index of gross and fine 291 
motor control and coordination. A third of the highly exposed children displayed a significant 292 
developmental delay (PDI <70) while the remaining were at risk (PDI <85). In comparison, only 293 
10% of the lighter and non-exposed children showed a significant delay and a third were at-risk. 294 
The lower PDI was maintained in heavily exposed children at 18 and 24 months of age (Singer et 295 
al., 2012b). Importantly, MDMA exposure did not affect the cognitive domain. A lower Mental 296 
Development Index (MDI) was observed in children at 12 months of age; however, the authors 297 
hypothesized that this effect could be related to the deficit of fine motor skills (Singer et al., 298 
2012b). This effect was no longer observed at later ages, and no other effects on language, 299 
emotional regulation or attention were observed (Singer et al., 2016).  300 
Another effect of MDMA exposure reported by Singer and colleagues (2012a) is that MDMA-301 
exposed infants were significantly more likely to be male (71% vs. 46%). Yet, the number of 302 
individuals is too low to draw a definite conclusion on MDMA effects on sex determination. They 303 
did not observe differences in other perinatal variables such as gestational length or probability 304 
of stillbirths, neither on other physical characteristics of the babies at birth (ie. birthweight, birth 305 
length; Singer et al., 2012a).  306 
The results described in the UK cohort demonstrate a robust and reliable effect of prenatal 307 
MDMA exposure on motor development, evidenced by the fact that motor delay was detected 308 
by different developmental scales and sustained through age. Additionally, the effects were 309 
statistically significant despite the small sample size after controlling for multiple confounding 310 
factors, including home environment, maternal stress and exposure to other drugs. It is 311 
important to note that all women included in the study reported to use MDMA during the first 312 
two trimesters, decreasing its use as the pregnancy advanced, while only one woman kept 313 
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consuming during the 3rd trimester. Therefore, the motor effects observed can be attributable 314 
to exposures during the beginning and middle of pregnancy. Additional studies are necessary to 315 
evaluate the effects of MDMA exposure during the third trimester, which is not likely to be 316 
possible using epidemiological studies. Furthermore, little is known about potential interactions 317 
between drugs in polydrug users. In the UK cohort, women who took MDMA during pregnancy 318 
were more likely to also take marijuana, cocaine, LSD, and mushrooms while pregnant (Moore 319 
et al., 2010; Singer et al., 2016).  320 
Taken all this together, more studies concerning prenatal exposure to MDMA are needed and a 321 
few considerations have to be taken into account. Despite the robustness of the UK cohort 322 
study, the sample of MDMA users, especially when divided between light (n= 15) and heavy 323 
users (n= 13; division based on a median split), was small. Recruiting larger samples is important 324 
to detect small effects with high variability, such as more subtle neurodevelopmental outcomes. 325 
Besides the inherent variability of neurodevelopmental parameters, another source of variation 326 
concerns the usage of MDMA between pregnant mothers with regards to duration, quantity or 327 
patterns of intake, which will in turn contribute to raise the variability in children outcomes. 328 
However, collecting large samples may be challenging because of social stigma associated to 329 
drug use, especially during pregnancy. As reported by the authors of the UK study this was a 330 
major drawback in recruiting subjects for their study. Another consideration refers to the 331 
method of exposure estimation. Although self-report may often be the only tool available to 332 
estimate drug intake, pregnancy follow-ups using hair or other biological samples would aid to 333 
validate self-reported usage and provide more accurate dosage estimates. Last, including a non-334 












Infant Evaluation Examiner Statistical Analyses Outcome Infants 
(Singer et al., 
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Fetal growth (weight, length, head 
circumference, gestational age) 
 
Health information from hospital 
records 
 
NICU Network Neurobehavioural 
Scale (NNNS) 
 
Alberta Infant Motor Scales 
(AIMS) 
 
Bayley Scales of Infant 
Development III (Mental 
Development Index (MDI), and 
Psychomotor Index (PDI), 
Behavioural Rating Scale (BRS)) 
 
Same examiner 
masked to infant 
drug 
status and trained 
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assistants or the 
equivalent and 




MDMA vs non-MDMA: chi-square or 
Fisher’s exact test and t- test or 
Wilcoxon Mann Whitney test 
 
Spearman correlation to assess 
relationships of amount and 




Multiple linear regression to 
determine significant predictors of 
the outcome measures controlling 
for covariates 
 
For three group analyses (heavy, 
light, non-user) Analyses of 
Variance (ANOVA) was used  
Child birth outcomes did not differ by group in gestation period, birthweight, 
prematurity 
 
Length and head circumference findings are inconclusive due to missing data 
 
MDMA-exposed infants were significantly more likely to be male (71% vs. 46%). 
 
NNNS 1mo: No differences between mean groups 
Non-significant trend to more lethargic behaviours and to manifest hypertonic 
responses  
 
Bayley 4mo: No differences in MDI or Attention/Arousal factor of the BRS 
BRS Motor Quality Scale: higher MDMA use over pregnancy predicting poorer motor 
quality: less coordinated and more likely to have slower and delayed movements  
Non-significant trend for heavily exposed MDMA infants to attain lower PDI scores 
than the other 2 groups (lighter/non-user). 
 
AIM 4mo: more heavily exposed MDMA infants performing less well than the non-
MDMA or the lighter MDMA-exposed groups 




Preschool Language Scale 
 
Bayley Scales of Infant 
Development III (MDI, PDI, BRS) 
 
== == Infants with heavier exposure 5-point deficit in MDI and motor outcomes: most at-risk 
(PDI <85), and 1/3 significant developmental delay (PDI ,70) 
 
Non-significant trend for MDMA exposure to predict less orientation and engagement  
 
MDMA exposure was unrelated to language or emotional regulation outcomes 
 




4, 12, 18 
and 24 
months 
Bayley Scales of Infant 
Development III (MDI, PDI, BRS) 
 
== Effects of MDMA (heavy, light, none) 
evaluated using repeated measures 
mixed model approach with a 
random intercept.  
 
An unstructured covariance matrix 
used to account for correlated 
responses within a subject.  
 
Effect of level of MDMA exposure on PDI over time: Heavier exposure 11-point deficit 
in PDI compared with lighter exposed children and a 6-point deficit compared to non-
exposed children over the first two years of life 
 
No effect of MDMA on the MDI: prior effect seen at 12 mo no longer significant once 
the overall trajectory of development was considered  
 
Significant effects of exposure on BRS motor quality: heavier MDMA exposure twice 
as likely to be rated by examiners as demonstrating poorer motor quality  
 
The Attention/Arousal subdomain of the BRS was measured only at 4 months. 
Heavier MDMA-exposed infants were perceived as having poorer attentional skills 
than lighter exposed infants and ns trend to perform more poorly than non-exposed 
infants  
 
No test age by MDMA interaction was found, indicating that the effects of MDMA on 
the outcomes did not significantly vary over the first two years of life. 
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3.2. Neurodevelopmental effects of developmental exposure to MDMA in animals in vivo. 263 
After the title and abstract screening, 65 articles on in vivo animal studies were included in the 264 
review. Full texts were collected and read for further evaluation according to the exclusion 265 
criteria and the ToxRTool – in vivo. From this analysis, 31 articles were excluded for the following 266 
reasons: one was a duplicate, two were secondary literature, three were not evaluating DNT, 267 
twenty-two were congress communications, one was excluded because of low quality (ToxRTool 268 
category 3), and two because the full-text could not be obtained. 269 
All remaining 34 studies included in this group were performed in rodents, with 30 rat and 5 270 
mouse studies (one study including both). Such a different proportion in the number of studies 271 
amongst these two species might be related to the knowledge acquired from adult neurotoxicity 272 
studies; adult neurotoxicity of MDMA is species-specific with induction of selective damage to 273 
serotonergic neurons in rats as well as most species examined including non-human primates 274 
(Green et al., 2003; Steele et al., 1994) and in contrast selective dopaminergic neurotoxicity in 275 
mice (O’Callaghan and Miller, 1994). According to Mueller and colleagues (2013), these different 276 
neurotoxicity profiles cannot be explained by differences in MDMA metabolism or 277 
pharmacokinetics of rats and mice. Probably, as the basis for these inter-species differences 278 
remain unknown, most study designs for developmental MDMA exposure choose rats because 279 
these belong to the rodent species which displays the most similarity in adult neurotoxicity to 280 
primate species. 281 
Besides using different species, a huge variety of experimental designs was applied in the animal 282 
in vivo studies. For a comprehensive review on the large methodological diversity and little 283 
consistency among preclinical studies assessing the effects of amphetamine-type stimulants 284 
(including MDMA) during pregnancy and lactation the reader is referred to McDonnell-Dowling 285 
and Kelly (2015). In this article the high variability of doses administered in studies evaluating 286 
developmental effects of MDMA is also discussed. In general, MDMA doses administered in 287 
animal studies are much higher than the ones regularly taken by young recreational ecstasy 288 
users. However, it has been proven that the application of common interspecies scaling 289 
strategies to compare MDMA doses between rodents and humans are not valid because in 290 
humans MDMA has a saturable kinetics (de la Torre et al., 2000). Thus, according to toxicokinetic 291 
studies in humans and rats reviewed by Green et al. (2009), to produce a similar peak blood 292 
plasma to that seen in humans after a 2 mg/kg dose, four fold higher doses are required in rats. 293 
Besides, the rapid MDMA clearance in this rodent species is also used by some authors to explain 294 
that repeated injections in rats would be the best strategy to mimic single oral doses in humans. 295 
Despite the large methodological heterogeneity observed in doses, number of administrations 296 
per day and exposure period, we present a summary of the results focusing on common adverse 297 
outcomes observed in rodent studies. 298 
Of the five studies performed in mice (Table 2 and Figure 2), three used a similar pattern of 299 
exposure: from fertilization or implantation to the end of lactation (gestational day (GD)1 or GD6 300 
to postnatal day (PND)21) with one oral administration daily and a common maximum dose of 301 
20 mg/kg b.w. (Cho et al., 2008; Kaizaki et al., 2014; Kwack et al., 2014). Cho and co-workers 302 
(2008) evaluated the effects of MDMA on neurogenesis using histological methods. They found 303 
a decreased number of BrdU labeled cells in the dentate gyrus 24h or 28 days after BrdU 304 
administration, indicating that developmental exposure to MDMA decreases the proliferation 305 
and survival of cells in the dentate gyrus. This observation is supported by similar findings in an 306 
acute dosage study with three i.p. doses of MDMA on PND6. In particular, they observed an 307 
increased cell degeneration determined by stereological cell counts in many of the 17 brain 308 
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regions analyzed, specially in the frontal, parietal and cingulate cortices, the septum, thalamus, 309 
hypothalamus and the cornu ammonis 1 region of the hippocampus. However, this effect was 310 
observed 24h after the exposure but not after 14 or 21 days (Dzietko et al., 2010). The other two 311 
studies with long gestational and postnatal exposure to MDMA evaluated different parameters 312 
of physical, functional and neuromotor maturation. While Kwack et al., (2014) did not find any 313 
adverse effect on physical development nor in motor reflexes, Kaizaki et al., (2014) linked MDMA 314 
exposure to delays in acquiring the righting reflex test, cliff-avoidance test and wire hanging 315 
maneuver, thus indicating alterations in reflexes and in motor development. However, the dose 316 
at which these behavioural adverse effects were observed (20 mg/kg b.w.), already produced a 317 
significant decrease in survival rate at PND4 and a significant decrease in body weight which 318 
makes it difficult to classify the adverse effects as specific DNT effects. The last study performed 319 
in mice (Eun et al., 2010) used a similar oral MDMA exposure paradigm, yet with a later onset of 320 
treatment (from GD15 to PND21, 20 mg/kg b.w.). Here, cell degeneration was not assessed 321 
because the study evaluated gene expression in the cerebral cortex of male and female offspring 322 
at PND77. Altered genes in mice developmentally treated with MDMA were related with 9 323 
common KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways: the MAPK signaling 324 
pathway, focal adhesion pathway, insulin signaling pathway, calcium signaling pathway, 325 
regulation of actin cytoskeleton, Wnt pathway, neuroactive ligand–receptor interaction 326 
pathway, axon guidance and colorectal cancer signaling. Although the timepoint of gene 327 
expression analyses (PND77) was too late to predict a developmental MDMA MoA, similar 328 
studies examining earlier timpoints possibly in a species reacting more similar to humans could 329 
be the basis for designing in vitro experiments that unravel the MDMA MoA of 330 
neurodevelopmental toxicity.  331 
Among the 30 studies performed in rats, the most common strain used was Sprague-Dawley. 332 
Only one study was performed in Long Evans and four in Wistar rats. A common limitation of 333 
these rat in vivo studies is the low number of dose-response studies that investigate more than 334 
two doses. Only five papers include three dose groups of MDMA plus the control to support the 335 
evaluation of dose-response relationships (Barenys et al., 2010; Broening et al., 2001, 1994; 336 
Dzietko et al., 2010; Vorhees et al., 2009, 2004). However, due to the overall low number of 337 
publications on the topic, single or two dose group studies were also considered in this review. 338 
Another limitation of most of the animal in vivo studies is the lack or reduced information on 339 
MDMA maternal or pup general toxicity. This deficiency makes the effect evaluation difficult to 340 
distinguish between DNT effects and general/maternal toxicity effects. Despite these 341 
limitations, there were common features seen in the rat in vivo studies that in the following 342 
paragraphs will be discussed according to five groups of studied endpoints, i.e. 343 




With twenty-one studies evaluating the effects of developmental exposure to MDMA on 348 
different neurotransmission related endpoints like concentrations of serotonin (5HT), dopamine 349 
(DA) or norepinephrine (NE) and their metabolites or binding to their transporters, this was the 350 
most studied group of endpoints among the articles reviewed (see Table 3 and Figure 3). 351 
Three studies evaluated the effects of MDMA on NEergic neurotransmission, and all of them 352 
found a significant increase in NE concentration, either in hippocampus, prefrontal cortex or 353 
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nucleus accumbens (Broening et al., 2001; Skelton et al., 2012; Thompson et al., 2012). Two of 354 
these studies exposed animals postnatally and observed the alteration in the hippocampus but 355 
not in other brain areas (Broening et al., 2001; Skelton et al., 2012), while if exposure occurred 356 
prenatally the effect was observed in the prefrontal cortex and nucleus accumbens but not in 357 
the hippocampus (Thompson et al., 2012). The only study evaluating norepinephrine transporter 358 
(NET) binding reported a significant increase also only in the hippocampus, while the 359 
concentration of NE metabolite MHPG (3-Methoxy-4-hydroxyphenylglycol) was not affected 360 
according to Thompson and colleagues (2012). From these in vivo results in rats the question 361 
arises if a proposed MoA involving effects of MDMA on the NE system can be related to the 362 
adverse outcome (AO) observed in children. An accumulation of NEergic neurons is positioned 363 
in the locus coeruleus located in the pons in vivo. Extensive coeruleo-cortical innervation is 364 
found to a variety of brain regions including the motor cortex suggesting that NE modulates the 365 
activity of these projected brain areas (Counts and Mufson, 2012). Indeed, mice lacking the 366 
ability to produce NE by knocking out the dopamine beta-hydroxylase (DBH) gene demonstrate 367 
the importance of NE during development and suggest that motor output is likely to be 368 
regulated by NE at both the central and peripheral level (Thomas and Palmiter, 1997). However, 369 
reduced NE causes reduced motor functions. In the MDMA treated rats, mainly increasing NE 370 
was measured in rat brains raising the question if indeed actions on the NE system are related 371 
to the decreased motor functions seen in children prenatally exposed to MDMA as described 372 
above. However, the NE system also controls arousal including stress response, attention, and 373 
memory function (Counts and Mufson, 2012). The human in vivo study observed a lower MDI 374 
early that was not observed at older ages (Singer et al., 2012b). It might be that the human brain 375 
has the ability to compensate for a non-functional NE system during development. This was 376 
suggested earlier based on the observation that patients with genetic DH-deficiency show 377 
remarkably normal cognitive functions (Jepma et al., 2011). In addition, there is an indication of 378 
NE dysregulation in human psychiatrial disease. NE was found hypersecreted in plasma in 379 
patients with unipolar depression and generalized anxiety (Sevy et al., 1989; Wyatt et al., 1971). 380 
If this dysregulation of the noradrenergic system is cause or consequence of these psychiatric 381 
diseases is not clear. However, long-term follow up of prenatally MDMA exposed children for 382 
their susceptibility to develop NE-related psychiatrial disorders seems desirable.  383 
Among 13 studies evaluating DA concentration in different brain areas, 12 found no significant 384 
effects, including studies performed during pre- or postnatal periods (Aguirre et al., 1998; 385 
Broening et al., 2001, 1994; Cohen et al., 2005; Colado et al., 1997; Galineau et al., 2005; Koprich 386 
et al., 2003a, 2003b; Meyer and Ali, 2002; Schaefer et al., 2008, 2006, 2012; Skelton et al., 2012). 387 
Only one study evaluated DA transporter binding and also detected no significant effects 388 
(Galineau et al., 2005). Concerning the effects of MDMA on concentrations of DA metabolites in 389 
specific brain areas, the results of ten studies were inconsistent. MDMA affected 3,4-390 
dihydroxyphenylacetic acid (DOPAC) concentrations only at higher doses (administering 40 391 
mg/kg b.w., 4x10 mg/kg b.w., 2x20 mg/kg b.w. or 2x15 mg/kg b.w.) (Broening et al., 1994; 392 
Koprich et al., 2003a, 2003b, Schaefer et al., 2012, 2008, 2006), while studies administering 393 
lower doses (10 mg/kg b.w., 2x10 mg/kg b.w. or 20 mg/kg b.w) caused no significant changes in 394 
DOPAC concentrations, independently of the administration period (pre- or postnatal) and 395 
length (1 to 10 days) (Aguirre et al., 1998; Cohen et al., 2005; Galineau et al., 2005; Meyer and 396 
Ali, 2002). For the positive studies, however, changes were not uniform. While some studies 397 
observed an increase in DOPAC concentration others measured decreases. Similarly, MDMA also 398 
affected another metabolite of DA, homovanillic acid (HVA). Three articles studying lower 399 
MDMA doses (10 mg/kg b.w., 2x10 mg/kg b.w. or 20 mg/kg b.w.) detected no significant changes 400 
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in HVA (Aguirre et al., 1998; Galineau et al., 2005; Meyer and Ali, 2002) while three articles 401 
including higher MDMA doses (40 mg/kg b.w., 2x20 mg/kg b.w. or 2x15 mg/kg b.w.) found 402 
significantly changed HVA concentrations in both directions, increased and decreased (Broening 403 
et al., 1994; Koprich et al., 2003a, 2003b). The reason for these inconsistent results on DA 404 
metabolite changes after MDMA exposure is not clear. As far as we can tell, there is not enough 405 
information to rule out that exposure scheme, timing or route of exposure or brain regions are 406 
related to the unequal effects of MDMA on DOPAC or HVA concentrations in rat brains. 407 
Nevertheless, we again ask the question if a proposed MoA involving effects of MDMA on the 408 
DAergic system can be related to the AO of decreased motor activity observed in children. 409 
Dopaminergic structures express connecting fibres to many different parts of the brain playing 410 
essential roles in aspects as simple as motivating basic movement and complex as cognition 411 
(Bissonette and Roesch, 2016). Moreover, DA is one of the earliest neurotransmitters occuring 412 
in the developing brain significantly shaping neuronal cytoarchitecture and circuitry by 413 
modulating cell proliferation, migration, and differentiation. Modifying DA receptor signaling 414 
during development alters amongst others tangential migration of GABAergic neurons possibly 415 
resulting in inappropriate neuronal excitation-inhibition balance in cortex. In addition, it 416 
modulates dendritic growth and the formation of dendritic spines, which, in the 417 
hyperdopaminergic DA transporter knockout mouse leads to the behavioural phenotype of 418 
hyperactivity (comprehensively reviewed in Money and Stanwood, 2013). Hence, 419 
developmental interference with the DA system is a possible MoA of MDMA causing behavioural 420 
abnormalities in children. Because dysregulation of the DAergic system also plays a fundamental 421 
role in neuropsychiatric disease later in life, follow-up studies of the children prenatally exposed 422 
towards MDMA in combination with human in vitro studies would shed more light on the 423 
mechanisms and consequences this exposure has in humans.  424 
Finally, the most studied neurotransmitter in MDMA DNT studies was 5HT, with 16 articles 425 
evaluating its concentrations at different times after MDMA developmental exposure (Aguirre 426 
et al., 1998; Broening et al., 2001, 1995, 1994; Cohen et al., 2005; Colado et al., 1997; Darvesh 427 
and Gudelsky, 2004; Galineau et al., 2005; Koprich et al., 2003a, 2003b; Meyer and Ali, 2002; 428 
Schaefer et al., 2012, 2008, 2006; Skelton et al., 2012; St Omer et al., 1991). Among these studies 429 
only 8 found adverse effects of MDMA on 5HT concentrations in different brain areas. However, 430 
if the brain area studied is restricted to the hippocampus, 8 out of 10 articles detected a 431 
significant decrease in 5HT concentration, while in other brain regions results were less 432 
homogeneous. Concentrations of the 5HT metabolite 5-Hydroxyindoleacetic acid (5-HIAA) were 433 
evaluated in 12 studies, among which 7 detected an adverse effect, with a very similar pattern 434 
than 5HT concentration alterations. If the brain region again is restricted to hippocampus, 5 out 435 
of 7 studies detected a significant decrease, and in this case, 5 out of 6 studies also reported a 436 
significant decrease in the concentration of the metabolite in the striatum. Ten studies 437 
evaluated effects on serotonin transporter binding. Surprisingly, adverse effects were detected 438 
only in three out of the four experiments administering MDMA from PND1 to PND4 and earlier 439 
or later exposures did not find adverse effects in this endpoint. Similar to DA, 5HT plays two key 440 
roles during development: during early development it acts as a growth factor by regulating cell 441 
division, differentiation, migration, myelination, synaptogenesis, and dendritic pruning before 442 
taking on its second role as a neurotransmitter in the mature brain regulating sensory and motor 443 
function, cognition, attention, emotion, pain, sleep and arousal (reviewed in Brummelte et al., 444 
2017; Shah et al., 2018). 5HT is also central to the development and function of two key stress 445 
response systems – the hypothalamic-pituitary–adrenal and the locus–coeruleus–NE systems 446 
that shape self-regulation and mental health across the lifespan and was already discussed 447 
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above (reviewed in Brummelte et al., 2017; Shah et al., 2018). From these functions two 448 
scenarios for how alteration of the 5HT system by MDMA can lead to the observed 449 
neurobehavioural effects in children can be envisioned. First, through a direct effect of MDMA 450 
on the serotoninergic system or secondly by indirectly interfering with the proper development 451 
of the locus coeruleus-NE system. Interestingly, the postnatal phase in rats is the most sensitive 452 
when it comes to MDMA interfering with serotonin transporter binding, as postnatal depletion 453 
of serotonin in rat pups via treatment with p-chlorophenylalanine (PCPA) leads to locomotor 454 
deficits (Vinay et al., 2005). MRI analyses in serotonin transporter Slc6a4 knockout mice clearly 455 
shows that despite the small number of 5HT neurons and their localization to the brainstem, 456 
5HT plays an important role in neuroanatomical organization (Ellegood et al., 2018). In terms of 457 
development of the serotonergic system the first postnatal weeks in rodents correspond to the 458 
3rd trimester of pregnancy in humans (Suri et al., 2015). 459 
Despite the multitude of studies describing effects of MDMA on neurotransmitter 460 
concentrations in developing brains, the precise MoA underlying the DNT of MDMA is still 461 
mysterious.  462 
 463 
Behavioural endpoints 464 
The second most studied group of endpoints following MDMA exposure was behaviour, 465 
evaluated in fourteen articles summarized inTable 4 and Figure 4 (Barenys et al., 2010; Broening 466 
et al., 2001; Canales and Ferrer-Donato, 2014; Cohen et al., 2005; Galineau et al., 2005; Heuland 467 
et al., 2010; Koprich et al., 2003b; Piper and Meyer, 2006; Schaefer et al., 2013; Skelton et al., 468 
2012; St Omer et al., 1991; Thompson et al., 2009; Vorhees et al., 2009, 2004). Here, locomotor 469 
behaviour was studied after pre- or postnatal MDMA exposure. Interestingly, time of exposure 470 
is crucial for the adverse outcome: exposure during gestation either causes no adverse effects 471 
in locomotion or significant hyperactivity (Canales and Ferrer-Donato, 2014; Koprich et al., 472 
2003b; St Omer et al., 1991; Thompson et al., 2009). In contrast, direct postnatal MDMA 473 
administration causes hypoactivity (Cohen et al., 2005; Skelton et al., 2012; Vorhees et al., 2009), 474 
independently of when during the postnatal period up to PND20 the exposure takes place. 475 
Therefore, among all exposure schemes reviewed, postnatal exposure towards MDMA produces 476 
the most similar effects in rat compared to human behaviour described in section 3.1. One major 477 
issue of pre- and postnatal exposure in rats compared to humans is the pre- and postnatal 478 
exposure routes. During gestation, in analogy to humans, the rat fetus is exposed to the test 479 
substance by transplacental transfer from the dam. However, postnatally rat pups’ chemical 480 
exposure happens through breast milk or in most of the reviewed studies by direct 481 
subcutaneous administration. In contrast, during the corresponding rat postnatal phase humans 482 
are still developing in utero (Clancy et al., 2007, 2001) and thus exposed through the placental 483 
route. This can lead to different exposure doses of parent compounds and/or their metabolites 484 
between the species (Tsuji and Crofton, 2012). If these kinetic issues, translating 485 
neurodevelopmental time differences and/or species differences are part of the reason why pre- 486 
and postnatal MDMA exposure causes such opposite effects only in rat offspring, yet not in 487 
children is currently enigmatic.  488 
Other behaviours commonly tested in a neurobehavioural testing battery are for example 489 
swimming/escape ability or spatial learning. No adverse effects were detected in any of the 490 
seven studies evaluating swimming/escape ability which included different pre- and postnatal 491 
exposure schemes (Broening et al., 2001; Cohen et al., 2005; Schaefer et al., 2013; Skelton et al., 492 
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2012; St Omer et al., 1991; Vorhees et al., 2009, 2004). These results reflect an equal 493 
performance in swimming and motivation in MDMA treated pups than in controls and are 494 
helpful to interpret results of other behavioural tests requiring swimming skills and motivation 495 
to escape. Such a commonly used behavioural test that combines swimming and motivation to 496 
escape with spatial learning skills is the Morris Water Maze (MWM). Drugs increasing 497 
serotonergic stimulation, like selective serotonin reuptake inhibitors, can have a positive 498 
influence on motivation and swimming behaviour in adult rats and thus modulate the 499 
performance in the MWM (Bogdanova et al., 2013). However, six out of seven articles found 500 
that MDMA impaired spatial learning in the MWM independent of altered swimming and 501 
motivation behaviour, which in most cases depended on the exposure period, being the latest 502 
postnatal period (PND10 to PND20) the most sensitive one (Broening et al., 2001; Schaefer et 503 
al., 2013; Skelton et al., 2012; Thompson et al., 2009; Vorhees et al., 2009, 2004). MDMA 504 
developmental exposure decreases serotonin content in the hippocampus (see 505 
Neurotransmission endpoints), yet other studies evaluating the effects of drugs producing 506 
depletion of serotonin, like PCPA, did not detect alterations in these behaviours in adult animals 507 
(Page et al., 1999). As neurotransmitters have trophic functions early during development which 508 
are clearly distinct from synaptic signal transmission, adult neurotoxicity studies might not be 509 
representative for developmental exposure in their outcomes. Brain regions implied in MWM  510 
navigation include  the  striatum  (Whishaw et al., 1987),  prefrontal  cortex (Mogensen et al., 511 
1995),  and  especially  the  hippocampus  (Morris et al., 1982), the latter being the brain region 512 
where most consistent effects of developmental MDMA exposure on neurotransmitter, 513 
especially 5HT concentrations were measured. Serotonergic lesions have already been related 514 
to severe spatial learning deficits in rats (Richter-Levin et al., 1994), which can be reduced by 515 
restoring the serotonergic innervation of the hippocampus by raphe grafts (Richter-Levin et al., 516 
1994). If indeed MDMA acts via the serotonergic system on rat behavior, i.e. spatial memory, 517 
and if there is any relevance of this behavioural change for humans needs further investigations. 518 
For all other behavioural tests studies were sparse and their results contradictory. Therefore, 519 
they could not be sufficiently evaluated within this review. 520 
General developmental landmarks 521 
Two of the studies analyzed included the evaluation of MDMA effects on general developmental 522 
landmarks (Table 5), as eye opening or incisor eruption (Heuland et al., 2010; St Omer et al., 523 
1991). The inclusion of these parameters is valuable as it helps to discern between general 524 
developmental delay and specific neurodevelopmental effects. Yet within the two studies 525 
including general developmental landmarks, opposite results were produced. While one study 526 
reported delayed eye opening and incisor eruption (Heuland et al., 2010) the second one did 527 
not find any of these developmental delays (St Omer et al., 1991). Exposure period in the positive 528 
study was shorter than the negative study and contained the same time frame. Moreover, the 529 
studies shared the maximum dose of MDMA (10 mg/kg b.w.). One explanation of the differences 530 
in result could be the rat strain used; general development of the Sprague-Dawley rat was 531 
unaffected by MDMA, while Wistar rat pups showed the developmental delay. Although these 532 
results are not conclusive, inclusion of such general developmental endpoints in 533 
neurodevelopmental studies is advisable. 534 
Effects on Growth Factors 535 
Out of the 30 studies in rats only 4 evaluated the effects of postnatal MDMA exposure on growth 536 
factor signaling (Dzietko et al., 2010; Koprich et al., 2003a; Piper et al., 2009; Schaefer et al., 537 
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2012). Growth factors studied were nerve growth factor (NGF), neurotrophin-3 (NT-3), and 538 
brain-derived neurotrophic factor (BDNF; see Table 6). None of the studies found alterations in 539 
NGF concentration or gene expression, while the only one evaluating effects in NT-3 detected a 540 
significant increase in its gene expression (Dzietko et al., 2010). All four studies included the 541 
evaluation of BDNF, but only two observed a significant increase in its gene or protein expression 542 
(Dzietko et al., 2010; Koprich et al., 2003a). In this case a general conclusion cannot be drawn 543 
from the data because exposure timing, strain and brain regions were all different in the studies.  544 
Other endpoints 545 
Among other endpoints tested (Table 7) it is worth mentioning two studies evaluating cell death 546 
and two more evaluating the effects of MDMA on neurite length and number of neurites per 547 
neuron. Cell death was detected in both studies after doses of 60 mg/kg, 3 x 20 mg/kg or 2x 10 548 
mg/kg (Dzietko et al., 2010; Meyer et al., 2004), especially after early postnatal exposure (until 549 
PND6), but not after later exposure (PND13 or PND20). Adverse effects in neurite length and 550 
number of neurites per neuron were also detected in both studies (Thompson et al., 2012; 551 
Williams et al., 2014) but not in all areas analyzed. One of these studies included prenatal 552 
exposure to 2x15 mg/kg of MDMA while the other one included postnatal exposure to 2x20 553 
mg/kg, so these results seem independent of the exposure period. During rodent late gestation, 554 
neurite outgrowth is modulated by DA (Money and Stanwood, 2013). Hence, a disturbance of 555 
the DAergic system by MDMA that is involved in neurite outgrowth may occur but has to be 556 
substantiated by experimental evidence. 557 
 558 
Figure 2. Heatmap summarizing the information about DNT studies of MDMA in vivo in mice collected in 559 
Table 2. Endpoints measured in a particular study are indicated with colored cells depending on the effect 560 
observed (increase – orange, decrease – blue, diverse effects – yellow) or the absence of effect (grey). For 561 
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Figure 3. Heatmap panels summarizing the information about DNT studies of MDMA in vivo in rats evaluating neurotransmission endpoints collected in Table 3. Endpoints 
measured in a particular study are indicated with colored cells depending on the effect observed (increase – orange, decrease – blue, diverse effects – yellow) or the absence 
of effect (grey). Cortical areas evaluated in the ‘Cortex’ panel are indicated in capital letters before the reference of each study. For more information about the details of 
each specific study, and the different brain areas included in the three studies of the panel ‘Other Brain Areas’ indicated with SEVERAL*, readers are referred to Table 3. 
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S.D. PND11-PND20 daily s.c. 5HT concentration HPLC Hippocampus PND142 - 2x 20mg/kg - -  
S.D. PND11-PND20 daily s.c. 5HT concentration HPLC Striatum PND142 - 2x 20mg/kg - - 
S.D. PND11-PND20 daily s.c. 5HT concentration HPLC Prefrontal cortex PND142 - 2x 20mg/kg - - 
S.D. PND11-PND20 daily s.c. 5-HIAA concentration HPLC Hippocampus PND142 PND142 2x 20mg/kg 2x 20mg/kg Decreased 
S.D. PND11-PND20 daily s.c. 5-HIAA concentration HPLC Striatum PND142 - 2x 20mg/kg - - 
S.D. PND11-PND20 daily s.c. 5-HIAA concentration HPLC Prefrontal cortex PND142 - 2x 20mg/kg - - 
S.D. PND11-PND20 daily s.c. DA concentration HPLC Striatum PND142 - 2x 20mg/kg - - 
S.D. PND11-PND20 daily s.c. DA concentration HPLC Prefrontal cortex PND142 - 2x 20mg/kg - - 
S.D. PND11-PND20 daily s.c. DOPAC concentration HPLC Striatum PND142 - 2x 20mg/kg - - 




S.D. PND 1–10 daily s.c. 5HT concentration  HPLC Hippocampus PND83 PND83 4x 10 and 4x 15 mg/kg 4x 10 mg/kg Decreased 
S.D. PND 6–15 daily s.c. 5HT concentration HPLC Hippocampus PND83 - 4x 10 and 4x 15 mg/kg -  - 
S.D. PND 11–20  daily s.c. 5HT concentration HPLC Hippocampus PND83 - 4x 10 and 4x 15 mg/kg -  - 
S.D. PND 1–10 daily s.c. 5HT concentration HPLC Enthorrinal cortex PND83 - 4x 10 and 4x 15 mg/kg -  - 
S.D. PND 6–15 daily s.c. 5HT concentration HPLC Enthorrinal cortex PND83 - 4x 10 and 4x 15 mg/kg -  - 
S.D. PND 11–20  daily s.c. 5HT concentration HPLC Enthorrinal cortex PND83 - 4x 10 and 4x 15 mg/kg -  - 
S.D. PND 1–10 daily s.c. 5HT concentration HPLC Prefrontal cortex PND83 - 4x 10 and 4x 15 mg/kg - -  
S.D. PND 6–15 daily s.c. 5HT concentration HPLC Prefrontal cortex PND83 - 4x 10 and 4x 15 mg/kg - -  
S.D. PND 11–20  daily s.c. 5HT concentration HPLC Prefrontal cortex PND83 PND83 4x 10 and 4x 15 mg/kg 4x 10 mg/kg  Decreased 
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S.D. PND 1–10 daily s.c. 5HT concentration HPLC Striatum PND83 PND83 4x 10 and 4x 15 mg/kg 4x 10 mg/kg   Increased 
S.D. PND 6–15 daily s.c. 5HT concentration HPLC Striatum PND83 - 4x 10 and 4x 15 mg/kg - - 
S.D. PND 11–20  daily s.c. 5HT concentration HPLC Striatum PND83 PND83 4x 10 and 4x 15 mg/kg 4x 15 mg/kg  Increased 
S.D. PND 1–10 daily s.c. NE concentration HPLC Hippocampus PND83 - 4x 10 and 4x 15 mg/kg -  - 
S.D. PND 6–15 daily s.c. NE concentration HPLC Hippocampus PND83 PND83 4x 10 and 4x 15 mg/kg 4x 15mg/kg  Increased 
S.D. PND 11–20  daily s.c. NE concentration HPLC Hippocampus PND83 - 4x 10 and 4x 15 mg/kg -  - 
S.D. PND 1–10 daily s.c. NE concentration HPLC Enthorrinal cortex PND83 - 4x 10 and 4x 15 mg/kg -  - 
S.D. PND 6–15 daily s.c. NE concentration HPLC Enthorrinal cortex PND83 - 4x 10 and 4x 15 mg/kg - - 
S.D. PND 11–20  daily s.c. NE concentration HPLC Enthorrinal cortex PND83 - 4x 10 and 4x 15 mg/kg - - 
S.D. PND 1–10 daily s.c. NE concentration HPLC Prefrontal cortex PND83 - 4x 10 and 4x 15 mg/kg -  - 
S.D. PND 6–15 daily s.c. NE concentration HPLC Prefrontal cortex PND83 - 4x 10 and 4x 15 mg/kg - - 
S.D. PND 11–20  daily s.c. NE concentration HPLC Prefrontal cortex PND83 - 4x 10 and 4x 15 mg/kg - - 
S.D. PND 1–10 daily s.c. NE concentration HPLC Striatum PND83 - 4x 10 and 4x 15 mg/kg -  - 
S.D. PND 6–15 daily s.c. NE concentration HPLC Striatum PND83 - 4x 10 and 4x 15 mg/kg - - 
S.D. PND 11–20  daily s.c. NE concentration HPLC Striatum PND83 - 4x 10 and 4x 15 mg/kg - - 
S.D. PND 1–10 daily s.c. DA concentration HPLC Hippocampus PND83 - 4x 10 and 4x 15 mg/kg -  - 
S.D. PND 6–15 daily s.c. DA concentration HPLC Hippocampus PND83 - 4x 10 and 4x 15 mg/kg - - 
S.D. PND 11–20  daily s.c. DA concentration HPLC Hippocampus PND83 - 4x 10 and 4x 15 mg/kg - - 
S.D. PND 1–10 daily s.c. DA concentration HPLC Enthorrinal cortex PND83 - 4x 10 and 4x 15 mg/kg -  - 
S.D. PND 6–15 daily s.c. DA concentration HPLC Enthorrinal cortex PND83 - 4x 10 and 4x 15 mg/kg - - 
S.D. PND 11–20  daily s.c. DA concentration HPLC Enthorrinal cortex PND83 - 4x 10 and 4x 15 mg/kg - - 
S.D. PND 1–10 daily s.c. DA concentration HPLC Prefrontal cortex PND83 - 4x 10 and 4x 15 mg/kg -  - 
S.D. PND 6–15 daily s.c. DA concentration HPLC Prefrontal cortex PND83 - 4x 10 and 4x 15 mg/kg -  - 
S.D. PND 11–20  daily s.c. DA concentration HPLC Prefrontal cortex PND83 - 4x 10 and 4x 15 mg/kg -  - 
S.D. PND 1–10 daily s.c. DA concentration HPLC Striatum PND83 - 4x 10 and 4x 15 mg/kg -  - 
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S.D. PND 6–15 daily s.c. DA concentration HPLC Striatum PND83 - 4x 10 and 4x 15 mg/kg - -  




Wistar GD6-GD20 e.o.d. s.c. DA concentration HPLC Striatum and 
hippothalamus 
PND15 - 20 mg/kg - - 
Wistar GD6-GD20 e.o.d. s.c. 5HT concentration HPLC Frontal cortex, 
striatum, hippocampus 
and hippothalamus 
PND15 - 20 mg/kg - - 




Frontal cortex and 
Hippoacampus 
PND15 - 20 mg/kg - - 
Wistar GD6-GD20 e.o.d. s.c. 5-HIAA concentration HPLC Frontal cortex, 
striatum, hippocampus 
and -hippothalamus  
PND15 - 20 mg/kg - - 
Wistar GD6-GD20 e.o.d. s.c. HVA concentration HPLC Frontal cortex, 
striatum, hippocampus 
and hippothalamus  
PND15 - 20 mg/kg - - 
Wistar GD6-GD20 e.o.d. s.c. DOPAC concentration HPLC Frontal cortex, 
striatum, hippocampus 
and hippothalamus  
PND15 - 20 mg/kg - - 
Wistar PND14 e.o.d. s.c. 5HT concentration HPLC Frontal cortex, 
striatum, hippocampus 
and hippothalamus  
PND21 - 20 mg/kg - - 
Wistar PND21 e.o.d. s.c. 5HT concentration HPLC Frontal cortex, 
striatum, hippocampus 
and hippothalamus 
PND28 - 20 mg/kg - - 
Wistar PND14 e.o.d. s.c. 5-HIAA concentration HPLC Frontal cortex, 
striatum, hippocampus 
and hippothalamus  
PND21 - 20 mg/kg - - 
Wistar PND21 e.o.d. s.c. 5-HIAA concentration HPLC Frontal cortex, 
striatum, hippocampus 
and hippothalamus  
PND28 - 20 mg/kg - - 
Wistar PND14 e.o.d. s.c. DA concentration HPLC Striatum and 
hippothalamus 
PND21 - 20 mg/kg - - 
Wistar PND21 e.o.d. s.c. DA concentration HPLC Striatum and 
hippothalamus 
PND28 - 20 mg/kg - - 
Wistar PND14 e.o.d. s.c. HVA concentration HPLC Frontal cortex, 
striatum, hippocampus 
and hippothalamus  
PND21 - 20 mg/kg - - 
22 
 
Wistar PND21 e.o.d. s.c. HVA concentration HPLC Frontal cortex, 
striatum, hippocampus 
and hippothalamus  
PND28 - 20 mg/kg - - 
Wistar PND14 e.o.d. s.c. DOPAC concentration HPLC Frontal cortex, 
striatum, hippocampus 
and hippothalamus  
PND21 - 20 mg/kg - - 
Wistar PND21 e.o.d. s.c. DOPAC concentration HPLC Frontal cortex, 
striatum, hippocampus 
and hippothalamus  
PND28 - 20 mg/kg - - 




Frontal cortex and 
Hippoacampus 
PND21 - 20 mg/kg - - 




Frontal cortex and 
Hippoacampus 





S.D. PND21 single 
day 




S.D. PND1-PND4 daily s.c. 5HT concentration HPLC Hippocampus PND25 PND25 2x 10 mg/kg 2x 10 mg/kg  Decreased 
S.D. PND1-PND4 daily s.c. HVA concentration HPLC Hippocampus PND25 - 2x 10 mg/kg -  - 
S.D. PND1-PND4 daily s.c. 5-HIAA concentration HPLC Hippocampus PND25 - 2x 10 mg/kg -  - 




Hippocampus PND25 PND25 2x 10 mg/kg 2x 10 mg/kg Decreased 




Hippocampus PND60 PND60 2x 10 mg/kg 2x 10 mg/kg  Decreased 
S.D. PND1-PND4 daily s.c. 5HT concentration HPLC Parietal cortex PND25 - 2x 10 mg/kg -  - 
S.D. PND1-PND4 daily s.c. DA concentration HPLC Parietal cortex PND25 - 2x 10 mg/kg -  - 
S.D. PND1-PND4 daily s.c. HVA concentration HPLC Parietal cortex PND25 - 2x 10 mg/kg -  - 
S.D. PND1-PND4 daily s.c. DOPAC concentration HPLC Parietal cortex PND25 - 2x 10 mg/kg -  - 
S.D. PND1-PND4 daily s.c. 5-HIAA concentration HPLC Parietal cortex PND25 - 2x 10 mg/kg -  - 




Parietal cortex PND25 - 2x 10 mg/kg -  - 




Parietal cortex PND60 PND60 2x 10 mg/kg 2x 10 mg/kg  Decreased 





Wistar GD14-GD17 daily s.c. DA concentration HPLC Dorsal telencephalon PND7 - 2x 20 mg/kg -  - 








Cortex PND70 - 2x 10 mg/kg -  - 








S.D. PND11 single 
day 
s.c. 5HT concentration HPLC Hippocampus PND12 PND12 4X 10 mg/kg 4X 10 mg/kg Decreased 
S.D. PND11-PND20 daily s.c. 5HT concentration HPLC Hippocampus PND21 PND21 4X 10 mg/kg 4X 10 mg/kg Decreased 
S.D. PND11-PND15 daily s.c. 5HT concentration HPLC Hippocampus PND16 PND16 4X 10 mg/kg 4X 10 mg/kg Decreased 
S.D. PND11 single 
day 
s.c. 5HT concentration HPLC Enthorrinal cortex PND12 PND12 4X 10 mg/kg 4X 10 mg/kg Decreased  
S.D. PND11-PND20 daily s.c. 5HT concentration HPLC Enthorrinal cortex PND21 PND21 4X 10 mg/kg 4X 10 mg/kg  Decreased 
S.D. PND11-PND15 daily s.c. 5HT concentration HPLC Enthorrinal cortex PND16 PND16 4X 10 mg/kg 4X 10 mg/kg  Decreased 
S.D. PND11 single 
day 
s.c. 5HT concentration HPLC Striatum PND12 PND12 4X 10 mg/kg 4X 10 mg/kg  Decreased 
S.D. PND11-PND20 daily s.c. 5HT concentration HPLC Striatum PND21 PND21 4X 10 mg/kg 4X 10 mg/kg  Decreased 
S.D. PND11-PND15 daily s.c. 5HT concentration HPLC Striatum PND16 - 4X 10 mg/kg -  - 
S.D. PND11-PND20 daily s.c. 5HT concentration HPLC Hippocampus PND60 PND60 4X 10 mg/kg 4X 10 mg/kg Decreased 
S.D. PND11-PND20 daily s.c. 5HT concentration HPLC Enthorrinal cortex PND60 - 4X 10 mg/kg -  - 
S.D. PND11-PND20 daily s.c. 5HT concentration HPLC Striatum PND60 - 4X 10 mg/kg -  - 
S.D. PND11 single 
day 
s.c. 5-HIAA concentration HPLC Hippocampus PND12 PND12 4X 10 mg/kg 4X 10 mg/kg  Decreased 
S.D. PND11 single 
day 
s.c. 5-HIAA concentration HPLC Enthorrinal cortex PND12 PND12 4X 10 mg/kg 4X 10 mg/kg  Decreased 
S.D. PND11 single 
day 
s.c. 5-HIAA concentration HPLC Striatum PND12 PND12 4X 10 mg/kg 4X 10 mg/kg  Decreased 
S.D. PND11-PND20 daily s.c. 5-HIAA concentration HPLC Hippocampus PND21 PND21 4X 10 mg/kg 4X 10 mg/kg  Decreased 
S.D. PND11-PND20 daily s.c. 5-HIAA concentration HPLC Enthorrinal cortex PND21 PND21 4X 10 mg/kg 4X 10 mg/kg  Decreased 
S.D. PND11-PND20 daily s.c. 5-HIAA concentration HPLC Striatum PND21 - 4X 10 mg/kg -  - 
S.D. PND11-PND15 daily s.c. 5-HIAA concentration HPLC Hippocampus PND16 PND16 4X 10 mg/kg 4X 10 mg/kg  Decreased 
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S.D. PND11-PND15 daily s.c. 5-HIAA concentration HPLC Enthorrinal cortex PND16 PND16 4X 10 mg/kg 4X 10 mg/kg  Decreased 
S.D. PND11-PND15 daily s.c. 5-HIAA concentration HPLC Striatum PND16 PND16 4X 10 mg/kg 4X 10 mg/kg  Decreased 
S.D. PND11 single 
day 
s.c. DA concentration HPLC Striatum PND12 - 4X 10 mg/kg -  - 
S.D. PND11-PND20 daily s.c. DA concentration HPLC Striatum PND21 - 4X 10 mg/kg -  - 
S.D. PND11-PND15 daily s.c. DA concentration HPLC Striatum PND16 - 4X 10 mg/kg -  - 
S.D. PND11 single 
day 
s.c. DOPAC concentration HPLC Striatum PND12 PND12 4X 10 mg/kg 4X 10 mg/kg  Decreased 
S.D. PND11-PND20 daily s.c. DOPAC concentration HPLC Striatum PND21 PND21 4X 10 mg/kg 4X 10 mg/kg  Increased 
S.D. PND11-PND15 daily s.c. DOPAC concentration HPLC Striatum PND16 - 4X 10 mg/kg -  - 
S.D. PND11-PND20 daily s.c. 5-HIAA concentration HPLC Hippocampus PND60 - 4X 10 mg/kg -  - 
S.D. PND11-PND20 daily s.c. 5-HIAA concentration HPLC Enthorrinal cortex PND60 - 4X 10 mg/kg -  - 
S.D. PND11-PND20 daily s.c. 5-HIAA concentration HPLC Striatum PND60 - 4X 10 mg/kg -  - 
S.D. PND11-PND20 daily s.c. DA concentration HPLC Striatum PND60 - 4X 10 mg/kg -  - 
S.D. PND11-PND20 daily s.c. DOPAC concentration HPLC Striatum PND60 - 4X 10 mg/kg -  - 
(Piper et 
al., 2009) 




Occipital cortex PND11, 
PND30 
PND30 2x 10 mg/kg 2x 10 mg/kg  Decreased 






PND11 2x 10 mg/kg 2x 10 mg/kg  Decreased 










S.D. PND11-PND20 daily s.c. 5HT concentration HPLC Frontal cortex PND21 PND21 2x 20 mg/kg 2x 20 mg/kg Decreased 
S.D. PND11-PND20 daily s.c. 5HT concentration HPLC Striatum PND21 PND21 2x 20 mg/kg 2x 20 mg/kg Decreased 
S.D. PND11-PND20 daily s.c. 5HT concentration HPLC Hippocampus PND21 PND21 2x 20 mg/kg 2x 20 mg/kg Decreased 
S.D. PND11-PND20 daily s.c. 5HT concentration HPLC Brainstem PND21 - 2x 20 mg/kg -  - 
S.D. PND11-PND20 daily s.c. 5-HIAA concentration HPLC Frontal cortex PND21 PND21 2x 20 mg/kg 2x 20 mg/kg Decreased 
S.D. PND11-PND20 daily s.c. 5-HIAA concentration HPLC Striatum PND21 PND21 2x 20 mg/kg 2x 20 mg/kg Decreased 
S.D. PND11-PND20 daily s.c. 5-HIAA concentration HPLC Hippocampus PND21 PND21 2x 20 mg/kg 2x 20 mg/kg Decreased 
S.D. PND11-PND20 daily s.c. 5-HIAA concentration HPLC Brainstem PND21 PND21 2x 20 mg/kg 2x 20 mg/kg Increased 
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S.D. PND11-PND20 daily s.c. DA concentration HPLC Frontal cortex PND21 - 2x 20 mg/kg -  - 
S.D. PND11-PND20 daily s.c. DA concentration HPLC Striatum PND21 - 2x 20 mg/kg -  - 
S.D. PND11-PND20 daily s.c. DA concentration HPLC Hippocampus PND21 - 2x 20 mg/kg -  - 
S.D. PND11-PND20 daily s.c. DA concentration HPLC Brainstem PND21 - 2x 20 mg/kg -  - 
S.D. PND11-PND20 daily s.c. DOPAC concentration HPLC Frontal cortex PND21 PND21 2x 20 mg/kg 2x 20 mg/kg Decreased 
S.D. PND11-PND20 daily s.c. DOPAC concentration HPLC Striatum PND21 PND21 2x 20 mg/kg 2x 20 mg/kg Increased 
S.D. PND11-PND20 daily s.c. DOPAC concentration HPLC Hippocampus PND21 - 2x 20 mg/kg -  - 
S.D. PND11-PND20 daily s.c. DOPAC concentration HPLC Brainstem PND21 - 2x 20 mg/kg -  - 
S.D. PND11-PND20 daily s.c. HVA concentration HPLC Frontal cortex PND21 PND21 2x 20 mg/kg 2x 20 mg/kg Increased 
S.D. PND11-PND20 daily s.c. HVA concentration HPLC Striatum PND21 PND21 2x 20 mg/kg 2x 20 mg/kg Increased 
S.D. PND11-PND20 daily s.c. HVA concentration HPLC Hippocampus PND21 PND21 2x 20 mg/kg 2x 20 mg/kg Increased 
S.D. PND11-PND20 daily s.c. HVA concentration HPLC Brainstem PND21 PND21 2x 20 mg/kg 2x 20 mg/kg Increased 
(Kelly et 
al., 2002) 




Cortex PND40 - 2x 20 mg/kg -  - 




Cortex PND40 - 2x 20 mg/kg -  - 




Cortex PND40 - 2x 20 mg/kg -  - 
 S.D. GD15-GD18 
and PND10-
PND13 








S.D. GD14-GD20 daily s.c. 5HT concentration HPLC Frontal cortex PND3 and 
PND21 
- 2x 15 mg/kg -  - 
S.D. GD14-GD20 daily s.c. 5HT concentration HPLC Striatum PND3 and 
PND21 
- 2x 15 mg/kg -  - 
 S.D. GD14-GD20 daily s.c. 5HT concentration HPLC Nucleus accumbens PND21 - 2x 15 mg/kg -  - 
 S.D. GD14-GD20 daily s.c. 5HT concentration HPLC Brainstem PND3 and 
PND21 
- 2x 15 mg/kg -  - 
 S.D. GD14-GD20 daily s.c. 5-HIAA concentration HPLC Frontal cortex PND3 and 
PND21 
- 2x 15 mg/kg -  - 
 S.D. GD14-GD20 daily s.c. 5-HIAA concentration HPLC Striatum PND3 and 
PND21 
PND21 2x 15 mg/kg 2x 15 mg/kg Decreased 
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 S.D. GD14-GD20 daily s.c. 5-HIAA concentration HPLC Nucleus accumbens PND21 PND21 2x 15 mg/kg 2x 15 mg/kg Decreased 
 S.D. GD14-GD20 daily s.c. 5-HIAA concentration HPLC Brainstem PND3 and 
PND21 
- 2x 15 mg/kg -  - 
 S.D. GD14-GD20 daily s.c. DA concentration HPLC Frontal cortex PND3 and 
PND21 
- 2x 15 mg/kg -  - 
 S.D. GD14-GD20 daily s.c. DA concentration HPLC Striatum PND3 and 
PND21 
- 2x 15 mg/kg -  - 
 S.D. GD14-GD20 daily s.c. DA concentration HPLC Nucleus accumbens PND21 - 2x 15 mg/kg -  - 
 S.D. GD14-GD20 daily s.c. DA concentration HPLC Brainstem PND3 and 
PND21 
- 2x 15 mg/kg -  - 
 S.D. GD14-GD20 daily s.c. DOPAC concentration HPLC Frontal cortex PND3 and 
PND21 
- 2x 15 mg/kg -  - 
 S.D. GD14-GD20 daily s.c. DOPAC concentration HPLC Striatum PND3 and 
PND21 
PND21 2x 15 mg/kg 2x 15 mg/kg Decreased 
 S.D. GD14-GD20 daily s.c. DOPAC concentration HPLC Nucleus accumbens PND21 - 2x 15 mg/kg -  - 
 S.D. GD14-GD20 daily s.c. DOPAC concentration HPLC Brainstem PND3 and 
PND21 
- 2x 15 mg/kg -  - 
 S.D. GD14-GD20 daily s.c. HVA concentration HPLC Frontal cortex PND3 and 
PND21 
- 2x 15 mg/kg -  - 




2x 15 mg/kg 2x 15 mg/kg Decreased 
 S.D. GD14-GD20 daily s.c. HVA concentration HPLC Nucleus accumbens PND21 - 2x 15 mg/kg -  - 
 S.D. GD14-GD20 daily s.c. HVA concentration HPLC Brainstem PND3 and 
PND21 
- 2x 15 mg/kg -  - 
 S.D. GD14-GD20 daily s.c. Tyrosine hydroxylase 
fiber density 
 IHC Frontal cortex PND21 PND21 2x 15 mg/kg 2x 15 mg/kg Increased 
 S.D. GD14-GD20 daily s.c. Tyrosine hydroxylase 
fiber density 
 IHC Striatum PND21 PND21 2x 15 mg/kg 2x 15 mg/kg Increased 
 S.D. GD14-GD20 daily s.c. Tyrosine hydroxylase 
fiber density 








Cerebrum PND29 - 2.5 and 10 mg/kg - - 
S.D. GD6-GD18 daily o.g. 5HT concentration HPLC Caudate nucleus, 
frontal cortex, or 
hippocampus 
PND27 - 2.5 and 10 mg/kg - - 
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S.D. GD6-GD18 daily o.g. 5-HIAA concentration HPLC Caudate nucleus, 
frontal cortex, or 
hippocampus 




S.D. PND11-PND15 daily s.c. DA concentration HPLC Striatum PND16 and 
PND30 
- 4X 10 mg/kg -  - 
S.D. PND11-PND15 daily s.c. DOPAC concentration HPLC Striatum PND16 and 
PND30 
- 4X 10 mg/kg -  - 
S.D. PND11-PND15 daily s.c. 5HT concentration HPLC Striatum PND16 and 
PND30 
PND16 4X 10 mg/kg 4X 10 mg/kg Decreased 
S.D. PND11-PND15 daily s.c. 5-HIAA concentration HPLC Striatum PND16 and 
PND30 
PND16 4X 10 mg/kg 4X 10 mg/kg Decreased 
S.D. PND11-PND15 daily s.c. 5HT concentration HPLC Hippocampus PND16 and 
PND30 
PND16 4X 10 mg/kg 4X 10 mg/kg Decreased 




4X 10 mg/kg 4X 10 mg/kg Decreased 
S.D. PND11-PND20 daily s.c. DA concentration HPLC Striatum PND21 and 
PND30 
- 4X 10 mg/kg -  - 
S.D. PND11-PND20 daily s.c. DOPAC concentration HPLC Striatum PND21 and 
PND30 
PND21 4X 10 mg/kg 4X 10 mg/kg Increased 
S.D. PND11-PND20 daily s.c. 5HT concentration HPLC Striatum PND21 and 
PND30 
PND21 4X 10 mg/kg 4X 10 mg/kg Decreased 
S.D. PND11-PND20 daily s.c. 5-HIAA concentration HPLC Striatum PND21 and 
PND30 
PND21 4X 10 mg/kg 4X 10 mg/kg Decreased 
S.D. PND11-PND20 daily s.c. 5HT concentration HPLC Hippocampus PND21 and 
PND30 
PND21 4X 10 mg/kg 4X 10 mg/kg Decreased 
S.D. PND11-PND20 daily s.c. 5-HIAA concentration HPLC Hippocampus PND21 and 
PND30 




S.D. PND11 single 
day 
s.c. DA concentration HPLC Striatum PND12 - 4X 10 mg/kg -  - 
S.D. PND11 single 
day 
s.c. DOPAC concentration HPLC Striatum PND12 PND12 4X 10 mg/kg 4X 10 mg/kg Decreased 
S.D. PND11 single 
day 
s.c. 5HT concentration HPLC Striatum PND12 PND12 4X 10 mg/kg 4X 10 mg/kg Decreased 
S.D. PND11 single 
day 
s.c. 5-HIAA concentration HPLC Striatum PND12 PND12 4X 10 mg/kg 4X 10 mg/kg Decreased 
S.D. PND11 single 
day 
s.c. 5HT concentration HPLC Hippocampus PND12 PND12 4X 10 mg/kg 4X 10 mg/kg Decreased 
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 S.D. PND11 single 
day 
s.c. 5-HIAA concentration HPLC Hippocampus PND12 PND12 4X 10 mg/kg 4X 10 mg/kg Decreased 
(Meyer et 
al., 2004) 
S.D. PND1-PND4 daily s.c. 5HT transporter 
density 
IHC Primary visual cortex 
 
PN month 9 PN month 9 2x 10 mg/kg 2x 10 mg/kg Decreased 
 
S.D. PND1-PND4 daily s.c. 5HT transporter 
density 
IHC Primary somatosensory 
cortex 
 
PN month 9 PN month 9 2x 10 mg/kg 2x 10 mg/kg Decreased 
  
S.D. PND1-PND4 daily s.c. 5HT transporter 
density 
IHC Caudate-putamen PN month 9 PN month 9 2x 10 mg/kg 2x 10 mg/kg Increased 
S.D. PND1-PND4 daily s.c. 5HT transporter 
density 
IHC Nucleus accumbens PN month 9 PN month 9 2x 10 mg/kg 2x 10 mg/kg Increased 
(Thompso
n et al., 
2012) 
S.D. GD14-GD20 daily s.c. NE transporter [3H] nisoxetine Hippocampus CA1 PND21 - 2x 15 mg/kg -  - 
S.D. GD14-GD20 daily s.c. NE transporter [3H] nisoxetine Hippocampus CA2 PND21 PND21 2x 15 mg/kg 2x 15 mg/kg Increased 
S.D. GD14-GD20 daily s.c. NE transporter [3H] nisoxetine Hippocampus CA3 PND21 PND21 2x 15 mg/kg 2x 15 mg/kg Increased 
S.D. GD14-GD20 daily s.c. NE transporter [3H] nisoxetine Hippocampus DG PND21 PND21 2x 15 mg/kg 2x 15 mg/kg Increased 
S.D. GD14-GD20 daily s.c. NE transporter [3H] nisoxetine Prefrontal cortex Cg3 PND21 - 2x 15 mg/kg -  - 
S.D. GD14-GD20 daily s.c. NE transporter [3H] nisoxetine Locus coeruleus PND21 - 2x 15 mg/kg -  - 
S.D. GD14-GD20 daily s.c. NE concentration HPLC Prefrontal cortex PND21 PND21 2x 15 mg/kg 2x 15 mg/kg Increased 
S.D. GD14-GD20 daily s.c. NE concentration HPLC Striatum PND21 - 2x 15 mg/kg -  - 
S.D. GD14-GD20 daily s.c. NE concentration HPLC Nucleus accumbens PND21 PND21 2x 15 mg/kg 2x 15 mg/kg Increased 
S.D. GD14-GD20 daily s.c. NE concentration HPLC Hippocampus PND21 - 2x 15 mg/kg -  - 
S.D. GD14-GD20 daily s.c. NE concentration HPLC Brainstem PND21 - 2x 15 mg/kg -  - 
S.D. GD14-GD20 daily s.c. MHPG concentration HPLC Prefrontal cortex PND21 - 2x 15 mg/kg -  - 
S.D. GD14-GD20 daily s.c. MHPG concentration HPLC Striatum PND21 - 2x 15 mg/kg -  - 




S.D. PND10 single 
day 
oral 5HT concentration HPLC Frontal cortex PND17 - 10, 20, 40 mg/kg -  - 
S.D. PND10 single 
day 
oral 5-HIAA concentration HPLC Frontal cortex PND17 - 10, 20, 40 mg/kg -  - 
S.D. PND10 single 
day 
oral 5HT concentration HPLC Hippocampus PND17 - 10, 20, 40 mg/kg -  - 
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S.D. PND10 single 
day 
oral 5-HIAA concentration HPLC Hippocampus PND17 - 10, 20, 40 mg/kg -  - 
S.D. PND10 single 
day 
oral 5HT concentration HPLC Caudate Putamen PND17 - 10, 20, 40 mg/kg -  - 
S.D. PND10 single 
day 
oral 5-HIAA concentration HPLC Caudate Putamen PND17 - 10, 20, 40 mg/kg -  - 
S.D. PND10 single 
day 
oral 5HT concentration HPLC Frontal cortex 3, 6, 12, 24, 
72, 120 and 
168h after 
MDMA 
3, 6, 12, 24h 
after MDMA 
40 mg/kg 40 mg/kg Decreased 
S.D. PND10 single 
day 
oral 5HT concentration HPLC Hippocampus 3, 6, 12, 24, 
72, 120 and 
168h after 
MDMA 
3, 6, 12, 24h 
after MDMA 
40 mg/kg 40 mg/kg Decreased 
S.D. PND10 single 
day 
oral 5HT concentration HPLC Caudate Putamen 3, 6, 12, 24, 
72, 120 and 
168h after 
MDMA 
3, 6, 12, 24h 
after MDMA 
40 mg/kg 40 mg/kg Decreased 
S.D. PND10 single 
day 




Frontal cortex 3, 6, 12, 24, 
72, 120 and 
168h after 
MDMA 
- 40 mg/kg -  - 
S.D. PND10 single 
day 
oral DA concentration HPLC Caudate Putamen 3, 6, 12, 24, 
72, 120 and 
168h after 
MDMA 
- 40 mg/kg -  - 
S.D. PND10 single 
day 
oral DOPAC concentration HPLC Caudate Putamen 3, 6, 12, 24, 





40 mg/kg 40 mg/kg Decreased 
S.D. PND10 single 
day 
oral HVA concentration HPLC Caudate Putamen 3, 6, 12, 24, 
72, 120 and 
168h after 
MDMA 
3, 6, 12, 24h 
after MDMA 




S.D. PND10 single 
day 
oral 5HT concentration HPLC Frontal cortex PND17 - 20, 40 mg/kg -  - 
S.D. PND10 single 
day 
oral 5HT concentration HPLC Hippocampus PND17 - 20, 40 mg/kg -  - 
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S.D. PND10 single 
day 
oral 5HT concentration HPLC Caudate Putamen PND17 - 20, 40 mg/kg -  - 
S.D. PND10 single 
day 








S.D. PND1-PND10 daily s.c. 5HT concentration HPLC Hippocampus PND105 PND105 2x5, 2x10, 2x20 mg/kg 2x 5 mg/kg Decreased 
S.D. PND11-PND20 daily s.c. 5HT concentration HPLC Hippocampus PND105 PND105 2x5, 2x10, 2x20 mg/kg 2x 5 mg/kg Decreased 
S.D. PND1-PND10 daily s.c. 5HT concentration HPLC Prefrontal cortex PND105 - 2x5, 2x10, 2x20 mg/kg -  - 
S.D. PND11-PND20 daily s.c. 5HT concentration HPLC Prefrontal cortex PND105 PND105 2x5, 2x10, 2x20 mg/kg 2x 5 mg/kg Decreased 
S.D. PND1-PND10 daily s.c. NE concentration HPLC Hippocampus PND105 PND105 2x5, 2x10, 2x20 mg/kg 2x 10 mg/kg Increased 
S.D. PND11-PND20 daily s.c. NE concentration HPLC Hippocampus PND105 PND105 2x5, 2x10, 2x20 mg/kg 2x 5 mg/kg Increased 
S.D. PND1-PND10 daily s.c. NE concentration HPLC Prefrontal cortex PND105 - 2x5, 2x10, 2x20 mg/kg -  - 
S.D. PND11-PND20 daily s.c. NE concentration HPLC Prefrontal cortex PND105 - 2x5, 2x10, 2x20 mg/kg -  - 
S.D. PND1-PND10 daily s.c. DA concentration HPLC Prefrontal cortex PND105 - 2x5, 2x10, 2x20 mg/kg -  - 




S.D. GD13-GD20 daily s.c. DA concentration HPLC Whole brain GD14, 16, 18, 
20, PND0, 7, 
14, 21 
- 10 mg/kg  -  - 
S.D. GD13-GD20 daily s.c. 5HT concentration HPLC Whole brain GD14, 16, 18, 
20, PND0, 7, 
14, 21 
PND0 10 mg/kg 10 mg/kg Decreased 
S.D. GD13-GD20 daily s.c. DOPAC concentration HPLC Whole brain GD14, 16, 18, 
20, PND0, 7, 
14, 21 
- 10 mg/kg  -  - 
S.D. GD13-GD20 daily s.c. HVA concentration HPLC Whole brain GD14, 16, 18, 
20, PND0, 7, 
14, 21 
- 10 mg/kg  -  - 
S.D. GD13-GD20 daily s.c. 5-HIAA concentration HPLC Whole brain GD14, 16, 18, 
20, PND0, 7, 
14, 21 
PND0 10 mg/kg 10 mg/kg Decreased 
S.D. GD13-GD20 daily s.c. 5HT transporter 
density 
[3H]MADAM Raphe nuclei, 
hypothalamus, 
somatosensory cortical 
areas, thalamus and 
hippocampus 
GD18, 20, 
PND0, 7, 14, 
21, 28, 70 
- 10 mg/kg  -  - 
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S.D. GD13-GD20 daily s.c. DA transporter 
density 






PND0, 7, 14, 
21, 28, 70 
- 10 mg/kg  -  - 
S.D. GD13-GD20 daily s.c. DA release Microdialysis Striatum PND70 PND70 10 mg/kg 10 mg/kg Decreased 
 S.D. GD13-GD20 daily s.c. 5HT release Microdialysis Hippocampus PND70 PND70 10 mg/kg 10 mg/kg Decreased 








Figure 4. Heatmap summarizing the information about DNT studies of MDMA in vivo in rats evaluating behavior related endpoints collected in Table 4. Endpoints measured 
in a particular study are indicated with colored cells depending on the effect observed (increase – orange, decrease – blue, diverse effects – yellow) or the absence of effect 













































S.D. 4 W pre-mating + 
3 W gestation +   








PND3 PND3 0.5, 5 and 10 mg/kg 10 mg/kg  Decreased 
 4 W pre-mating + 
3 W gestation +   






Tail-hang reflex PND21 - 0.5, 5 and 10 mg/kg -  - 
 4 W pre-mating + 
3 W gestation +   








PND21 - 0.5, 5 and 10 mg/kg -  - 
 4 W pre-mating + 
3 W gestation +   


















- 2x 10 mg/kg - - 
Long 
Evans 
GD13–GD15  daily o.g. Locomotor 
activity 




S.D. PND11-PND20  daily s.c. Spatial learning MWM PND115-
PND125 
- 2x 20mg/kg - - 




- 2x 20mg/kg - - 




PND139 - 2x 20mg/kg - - 
S.D. PND11-PND20 daily s.c. Anxiety Elevated Zero 
Maze 
PND107 - 2x 20mg/kg - - 
S.D. PND11-PND20 daily s.c. Locomotor 
activity 
Open-field test PND140 PND140 2x 20mg/kg 2x 20mg/kg Lower total distance 




S.D. PND11-PND20 daily s.c. Swimming/ 
escape 











10 mg/kg  -  - 










S.D. PND11-PND20 daily s.c. Swimming/ 
escape 
Straight channel PD61 - 4x 10 mg/kg - - 
S.D. PND11-PND20 daily s.c. Spatial learning MWM PD80-88 PND80-
PND88 
4x 10 mg/kg 4x 10 mg/kg Worse acquisition, 
retention and reversal 
S.D. PND11-PND20 daily s.c. Egocentric 
learning 
Cincinnati maze PD62-80 PND62-
PND80 







daily s.c. Sensory and 
locomotor 




daily s.c. Sensory and 
locomotor 
PPI PND60 PND60 4x10 and 4x15 mg/kg - - 
S.D. PND11-PND20  daily s.c. Sensory and 
locomotor 
PPI PND60 PND60 4x10 and 4x15 mg/kg - - 
S.D. PND1-PND10 daily s.c. Swimming/ 
escape 
Straight channel PND61 - 4x10 and 4x15 mg/kg - - 
S.D. PND6-PND15 
 
daily s.c. Swimming/ 
escape 
Straight channel PND61 - 4x10 and 4x15 mg/kg - - 
S.D. PND11-PND20 daily s.c. Swimming/ 
escape 
Straight channel PND61 - 4x10 and 4x15 mg/kg - - 
S.D. PND1-PND10 daily s.c. Egocentric 
learning 
Cincinnati maze PND62-PND80 PND62-
PND80 
4x10 and 4x15 mg/kg - - 
S.D. PND6-PND15 
 
daily s.c. Egocentric 
learning 
Cincinnati maze PND62-PND80 PND62-
PND80 
4x10 and 4x15 mg/kg 4x10 mg/kg Worse performance 
S.D. PND11-PND20 daily s.c. Egocentric 
learning 
Cincinnati maze PND62-PND80 PND62-
PND80 
4x10 and 4x15 mg/kg 4x10 mg/kg Worse performance 
S.D. PND1-PND10 daily s.c. Spatial learning MWM PND62-PND80 PND62-
PND80 
4x10 and 4x15 mg/kg 4x10 mg/kg Worse acquisition 
S.D. PND6-PND15 
 
daily s.c. Spatial learning MWM PND62-PND80 PND62-
PND80 
4x10 and 4x15 mg/kg 4x10 mg/kg Worse acquisition and 
reversal 
S.D. PND11-PND20 daily s.c. Spatial learning MWM PND62-PND80 PND62-
PND80 
4x10 and 4x15 mg/kg 4x10 mg/kg Worse acquisition, 
retention and reversal 
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S.D. PND1-PND10 daily s.c. Associative 
learning 
Fear Conditioning PND81-PND82 PND81-
PND82 




daily s.c. Associative 
learning 
Fear Conditioning PND81-PND82 PND81-
PND82 
4x10 and 4x15 mg/kg - - 
S.D. PND11-PND20 daily s.c. Associative 
learning 
Fear Conditioning PND81-PND82 PND81-
PND82 
4x10 and 4x15 mg/kg - - 
S.D. PND1-PND10 daily s.c. Locomotor 
activity 




daily s.c. Locomotor 
activity 
Open-field test PND81 PND81 4x10 and 2x15 mg/kg 4x10 mg/kg Reduced locomotor 
activity 
S.D. PND11-PND20 daily s.c. Locomotor 
activity 
Open-field test PND81 PND81 4x10 and 2x15 mg/kg 4x10 mg/kg Reduced locomotor 
activity 
S.D. PND1-PND10 daily s.c. NMDAR 
sensitivity 
MK-801 challenge 
in Open Field 
PND82 PND82 4x10 and 4x15 mg/kg 4x10 mg/kg Reduced MK-801-
induced hyperactivity  
S.D. PND6-PND15 
 
daily s.c. NMDAR 
sensitivity 
MK-801 challenge 
in Open Field 
PND82 PND82 4x10 and 4x15 mg/kg 4x10 mg/kg Reduced MK-801-
induced hyperactivity  
S.D. PND11-PND20 daily s.c. NMDAR 
sensitivity 
MK-801 challenge 
in Open Field 
PND82 PND82 4x10 and 4x15 mg/kg 4x10 mg/kg - 
(Thomps
on et al., 
2009) 




PND40-PND50 - 2x 15 mg/kg -  - 
S.D. GD14-GD20 daily s.c. Locomotor 
activity 
Running wheel PND36-PND39 - 2x 15 mg/kg -  - 
S.D. GD14-GD20 daily s.c. Locomotor 
activity 
Open-field test PND61-PND62 PND61-62 2x 15 mg/kg 2x 15 mg/kg Hyperactivity 
S.D. GD14-GD20 daily s.c. Reward system High Fat Diet PND132-
PND145 
- 2x 15 mg/kg -  - 
S.D. GD14-GD20 daily s.c. Reward system Progressive ratio 
sucrose 
PND58 - 2x 15 mg/kg -  - 
S.D. GD14-GD20 daily s.c. Reward system Amphetamine 
sensitization 
PND120 - 2x 15 mg/kg -  - 




- 2x 15 mg/kg - - 





PND40 - 2x 15 mg/kg - - 
S.D. GD14-GD20 daily s.c. Spatial learning MWM PND53-PND72 PND69-73 2x 15 mg/kg 2x 15 mg/kg Preference for the local 








S.D. PND1-PND5 daily s.c. Anxiety Elevated Zero 
Maze 
PND60 - 4x10, 4x15, 4x20, or 
4x25 mg/kg 
- - 
S.D. PND6-PND10 daily s.c. Anxiety Elevated Zero 
Maze 





daily s.c. Anxiety Elevated Zero 
Maze 
PND60 - 4x10, 4x15, 4x20, or 
4x25 mg/kg 
- - 
S.D. PND16-PND20 daily s.c. Anxiety Elevated Zero 
Maze 
PND60 - 4x10, 4x15, 4x20, or 
4x25 mg/kg 
- - 




daily s.c. Locomotor 
activity 
Open-field test PND61 PND61 4x10, 4x15, 4x20, or 
4x25 mg/kg 
4x15 mg/kg Decreased distance 


































S.D. PND1-PND5 daily s.c. Swimming/ 
escape 
Straight channel PND67 - 4x10, 4x15, 4x20, or 
4x25 mg/kg 
- - 
S.D. PND6-PND10 daily s.c. Swimming/ 
escape 





daily s.c. Swimming/ 
escape 
Straight channel PND67 - 4x10, 4x15, 4x20, or 
4x25 mg/kg 
- - 
S.D. PND16-PND20 daily s.c. Swimming/ 
escape 
Straight channel PND67 - 4x10, 4x15, 4x20, or 
4x25 mg/kg 
- - 
S.D. PND1-PND5 daily s.c. Egocentric 
learning 
Cincinnati maze PND68-PND83 - 4x10, 4x15, 4x20, or 
4x25 mg/kg 
- - 
S.D. PND6-PND10 daily s.c. Egocentric 
learning 





daily s.c. Egocentric 
learning 
Cincinnati maze PND68-PND83 - 4x10, 4x15, 4x20, or 
4x25 mg/kg 
- - 
S.D. PND16-PND20 daily s.c. Egocentric 
learning 









4x10, 4x15, 4x20, or 
4x25 mg/kg 
4x10 mg/kg Impaired learning 




4x10, 4x15, 4x20, or 
4x25 mg/kg 
4x10 mg/kg Impaired learning 
S.D. PND11-PND15 
 




4x10, 4x15, 4x20, or 
4x25 mg/kg 
4x10 mg/kg Impaired learning 




4x10, 4x15, 4x20, or 
4x25 mg/kg 









PND69 - 2x 10 mg/kg -  - 








S.D. GD14-GD20 daily s.c. Learning and 
locomotor 











PND2 to PND5 - 2.5 and 10 mg/kg -  - 
S.D. GD6-GD18 daily o.g. Negative 
geotaxis 




2.5 and 10 mg/kg 2.5 mg/kg Only in females 








- 2.5 and 10 mg/kg -  - 




PND9 - PND11 PND10 and 
PND11 
2.5 and 10 mg/kg 2.5 and 10 
mg/kg 
Only males at 2.5 
mg/kg in PND10 and 
only females at 10 
mg/kg in PND11 







- 2.5 and 10 mg/kg -  - 




PND6 - 2.5 and 10 mg/kg -  - 






- 2.5 and 10 mg/kg -  - 











g et al., 
2001) 
S.D. PND1-PND10 daily s.c. Swimming/ 
escape 
Straight channel PND60 - 2x5, 2x10, 2x20 mg/kg -  - 
S.D. PND11-PND20 daily s.c. Swimming/ 
escape 
Straight channel PND60 - 2x5, 2x10, 2x20 mg/kg -  - 
S.D. PND1-PND10 daily s.c. Sequential 
learning 
Multiple t-maze PND63 PND63 2x5, 2x10, 2x20 mg/kg 2x10 mg/kg Worst performance: 
errors increase 
S.D. PND11-PND20 daily s.c. Sequential 
learning 
Multiple t-maze PND63 PND63 2x5, 2x10, 2x20 mg/kg 2x5 mg/kg Worst performance: 
errors and latency 
increase  
S.D. PND1-PND10 daily s.c. Cued learning MWM PND70 - 2x5, 2x10, 2x20 mg/kg -  - 
S.D. PND11-PND20 daily s.c. Cued learning MWM PND70 - 2x5, 2x10, 2x20 mg/kg -  - 
S.D. PND1-PND10 daily s.c. Spatial learning MWM PND77 - 2x5, 2x10, 2x20 mg/kg -  - 
S.D. PND11-PND20 daily s.c. Spatial learning MWM PND77 PND77 2x5, 2x10, 2x20 mg/kg 2x5 mg/kg Worst performance: 
increase in latency, 
path length, cumulative 
distance (reduced trials 
for spatial learning) and 






S.D. PND11-PND20 daily s.c. Swimming/ 
escape 
Straight channel PND61 - 2x5, 2x10, 2x20 mg/kg -  - 
S.D. PND11-PND20 daily s.c. Spatial learning MWM PND62 or 
PND77 
PND62 2x5, 2x10, 2x20 mg/kg 2x5 mg/kg Increased latency at 5 
mg/kg, increased path 
lenght at 10 mg/kg, 
increased cumulative 
distance and increased 
average distance to 
target at 20 mg/kg (only 
when MWM performed 
before Barnes maze)  
 
S.D. PND11-PND20 daily s.c. Cued learning MWM PND62 or 
PND77 
- 2x5, 2x10, 2x20 mg/kg - - 
S.D. PND11-PND20 daily s.c. Working 
memory 




u et al., 
2005) 
S.D. GD13-GD20 daily s.c. Sucrose 
preference 
  PND70 PND70 10 mg/kg 10 mg/kg Decreased 





Table 5. Summary of DNT studies of MDMA in vivo in rats evaluating general developmental landmarks related endpoints. 




































Wistar GD13-GD20 daily s.c. Eyes opening External 
examination 
PND2-PND21 PND15 10 mg/kg 10 mg/kg Delay 
Wistar GD13-GD20 daily s.c. Incisor eruption External 
examination 








- 2.5 and 10 mg/kg - - 




- 2.5 and 10 mg/kg - - 
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Table 6. Summay of DNT studies of MDMA in vivo in rats evaluating growth factor related endpoints. 




















































Wistar PND6 single day i.p. BDNF Gene expression - PND7 PND7 (6h a.i.) 20 mg/kg 20 mg/kg Increase 
 PND6 single day i.p. BDNF Gene expression - PND7 PND7 (6h a.i.) 60 mg/kg 60 mg/kg Increase 
 PND6 single day i.p. NT-3 Gene expression - PND7 PND7 (6h a.i.) 60 mg/kg 60 mg/kg Increase 
 PND6 single day i.p. NGF Gene expression - PND7 - 60 mg/kg - - 




S.D. PND11 single day s.c. BDNF HPLC Striatum PND12 - 4X 10 mg/kg - - 
 PND11-PND20 daily s.c. BDNF HPLC Striatum PND21 - 4X 10 mg/kg - - 
 PND11-PND15 daily s.c. BDNF HPLC Striatum PND16 - 4X 10 mg/kg - - 
 PND11 single day s.c. NGF HPLC Striatum PND12 - 4X 10 mg/kg - - 
 PND11-PND20 daily s.c. NGF HPLC Striatum PND21 - 4X 10 mg/kg - - 
 PND11-PND15 daily s.c. NGF HPLC Striatum PND16 - 4X 10 mg/kg - - 
(Piper et 
al., 2009) 
S.D. PND1-PND4 daily s.c. BDNF Immunoassay Occipital cortex PND11, PND30, PND65 - 2x 10 mg/kg - - 
 PND1-PND4 daily s.c. BDNF Immunoassay Hippocampus PND11, PND30, PND65 - 2x 10 mg/kg - - 




S.D. PND11-PND20 daily s.c. BDNF ELISA Hippocampus PND21 PND21 2x 20 mg/kg 2x 20 mg/kg Increase 
 PND11-PND20 daily s.c. BDNF ELISA Frontal cortex PND21 PND21 2x 20 mg/kg 2x 20 mg/kg Increase 
 PND11-PND20 daily s.c. BDNF ELISA Striatum PND21 PND21 2x 20 mg/kg 2x 20 mg/kg Increase 
 PND11-PND20 daily s.c. BDNF ELISA brainstem PND21 PND21 2x 20 mg/kg 2x 20 mg/kg Increase 
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GD3–GD15  daily o.g. Proliferation  BrdU 
incorporation 
Dentate Gyrus PND111 - 2x 10 mg/kg -  - 
(Cohen et al., 
2005) 
S.D. PND11-PND20 daily s.c. Body Temperature Temperature  - P82–100 P82–100 2x 20mg/kg - - 
S.D. PND11-PND20 daily s.c. Organ weight Weight measure  Thymus P142 - 2x 20 mg/kg - - 
(Dzietko et al., 
2010) 
Wistar PND6 single 
day 
i.p. Cell death IHC Globarl score 
including 17 brain 
regions 
PND7 PND7 20, 40, 60 
mg/kg 
60 mg/kg Increased 
Wistar PND6 single 
day 
i.p. Cell death IHC Globarl score 
including 17 brain 
regions 
PND7 PND7 3x 20 mg/kg 3x 20 mg/kg Increased 
Wistar PND13 single 
day 
i.p. Cell death IHC Globarl score 
including 17 brain 
regions 
PND14 - 60 mg/kg - - 
Wistar PND20 single 
day 
i.p. Cell death IHC Globarl score 
including 17 brain 
regions 




S.D. PND21 single 
day 
s.c. Brain glycogen  Fluorimetric assay Caudal quarter of 
the left cerebral 
hemisphere 
PND28 PND28 20 mg/kg 20 mg/kg Decreased (when 
evaluated at 24ºC, but not 
when evaluated at 17ºC)  
(Colado et al., 
1997) 
Wistar PND7 single 
day 
s.c. Lipid peroxidation Malondialdehyde 
formation 
Cortex  PND7 - 40 mg/kg -  - 
(Williams et 
al., 2014) 
S.D. PND11-PND20 daily s.c. Dendrite length Golgi-Cox 
analysis 
Enthorrinal cortex PND60 PND60 2x 20 mg/kg 2x 20 mg/kg Decreased 




PND60 PND60 2x 20 mg/kg 2x 20 mg/kg Decreased 
S.D. PND11-PND20 daily s.c. Dendrite length Golgi-Cox 
analysis 
Dentate gyrus PND60 PND60 2x 20 mg/kg 2x 20 mg/kg   Decreased 
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S.D. PND11-PND20 daily s.c. Dendrite length Golgi-Cox 
analysis 
Frontal cortex PND60 - 2x 20 mg/kg -  - 




Enthorrinal cortex PND60 - 2x 20 mg/kg -  - 






PND60 PND60 2x 20 mg/kg 2x 20 mg/kg Decreased 




Dentate gyrus PND60 PND60 2x 20 mg/kg 2x 20 mg/kg Increased 




Frontal cortex PND60 - 2x 20 mg/kg - - 
(Kelly et al., 
2002) 




25 brain areas PND90 PND90 2x 20 mg/kg 2x 20 mg/kg Increased in locus 






septal nucleus, globus 
pallidus  




25 brain areas PND90 - 2x 20 mg/kg - - 
(Meyer et al., 
2004) 
S.D. PND1-PND4 daily s.c. Cell death IHC Forebrain PND5 PND5 2x 10 mg/kg 2x 10 mg/kg Increased 
S.D. PND1-PND4 daily s.c. Cell death IHC Hippocampus PND5 PND5 2x 10 mg/kg 2x 10 mg/kg Increased  
(Thompson et 
al., 2012) 
S.D. GD14-GD20 daily s.c. Noradrenergic 
neurites 
DBH Prefrontal cortex 
Cg3 
PND21 PND21 2x 15 mg/kg 2x 15 mg/kg Increased 
S.D. GD14-GD20 daily s.c. Noradrenergic 
neurites 
DBH Hippocampus CA1 PND21 PND21 2x 15 mg/kg 2x 15 mg/kg Increased 
S.D. GD14-GD20 daily s.c. Noradrenergic 
neurites 
DBH Hippocampus CA2 PND21 - 2x 15 mg/kg - - 
S.D. GD14-GD20 daily s.c. Noradrenergic 
neurites 
DBH Hippocampus CA3 PND21 - 2x 15 mg/kg - -  
S.D. GD14-GD20 daily s.c. Noradrenergic 
neurites 
DBH Hippocampus DG PND21 - 2x 15 mg/kg -  - 
S.D. GD14-GD20 daily s.c. Noradrenergic 
neuron count 
DBH Locus coeruleus PND21 - 2x 15 mg/kg -   




3.3. In vitro studies on neurodevelopmental effects of MDMA. 568 
Based on title and abstract screening according to the predefined criteria (see 2.2) 15 569 
publications were selected from the in vitro studies for full text screening. During the full-text 570 
reading and acquisition of data 13 articles were excluded because of the following reasons: one 571 
did not include MDMA exposure, one was performed in chicken (see exclusion criteria), three 572 
obtained category 3 in ToxRTool (not reliable), and eight did not evaluate neurodevelopmental 573 
endpoints. Among the latter, two studies by Keating and colleagues were excluded, however, 574 
the authors demonstrated that MDMA affects folic acid uptake by human cytotrophoblasts and 575 
might thereby indirectly affect folic acid-dependent processes during brain development 576 
(Keating et al., 2009, 2007). 577 
From the two publications that were selected based on the full text screen (Table 8), one 578 
publication used rat mesencephalic neuronal cultures from embryonic day four (E4), which were 579 
treated for 96 hours with MDMA starting from day in vitro (DIV) 0 (Lipton et al., 2008). The 580 
second one employed mouse embryonic stem cells (mESC, Royan B1) and treated them for 10 581 
days during embryoid body formation (Meamar et al., 2010). Experimental cell models, species 582 
and endpoints were completely different between the two studies. This is the reason why they 583 
are discussed separately here. In rat mesencephalic neuronal cultures MDMA (LOAEC 0,75 µM) 584 
increased the number of TH+ cells. This effect was stronger when MDMA was administered early, 585 
i.e. from 0 to 2 DIV with no exposure from 2 to 4 DIV, compared to late exposure, i.e. no MDMA 586 
between 0 and 2 DIV and exposure from 2 DIV to 4 DIV. In two in vivo studies, MDMA increased 587 
the number of TH+ neurons on PND35 in the substantia nigra of prenatally (GD14-GD20) MDMA 588 
exposed rats (Lipton et al., 2008) as well as on PND21 (Koprich et al., 2003b). One of the earliest 589 
effects of DA in the developing brain is cell cycle regulation of specific neural progenitor cells. 590 
DA causes D1 receptor-dependent cell cycle inhibition with reduction of proliferation of a neural 591 
progenitor cells pool that is the source for most striatal neurons (Money and Stanwood, 2013).  592 
The second in vitro study used embroid bodies, which were produced from mESC and 593 
subsequently differentiated towards the neural lineage due to retinoic acid treatment. MDMA 594 
exposure during the whole differentiation period (10 DIV) decreased neurite outgrowth (IC50 50 595 
µM) and MAP2 gene expression (LOAEC= 10 µM; Meamar et al., 2010). Shorter dendrites after 596 
postnatal MDMA exposure were also found at PND60 in rats in the nucleus accumbens, the 597 
dentate gyrus and the entorhinal cortex (Williams et al., 2014) indicating that neuronal 598 
cytoarchitectural changes induced by MDMA developmental exposure are long-lasting in vivo. 599 
Moreover, these cytoarchitectural changes appear in regions consistent with the spatial learning 600 
deficits described in the in vivo section (Williams et al., 2014). Neurite outgrowth can be affected 601 
by a variety of MoA, one being interference with the DAergic system (Money and Stanwood, 602 
2013). As the in vitro study (Meamar et al., 2010) did not investigate the MoA of MDMA 603 
inhibiting neurite outgrowth, more data is clearly needed to unravel the molecular mechanism 604 
underlying MDMA DNT. 605 
 606 
3.4 Generation of hypothetical AOPs from collected data 607 
This review collected available data on the adverse effects of the recreational drug MDMA on 608 
the brain during development. The outcomes of human and rodent in vivo as well as rodent in 609 
vitro studies were collected, discussed, and subsequently assembled in hypothetical AOPs (Fig. 610 
5). For general introduction to the AOP conceptual framework and specific vocabulary (MIE: 611 
molecular initiating event, KE: key event, KER: key event relationship and AO), the reader is 612 
referred to the following publications: (Ankley et al., 2010; Bal-Price et al., 2017). The anchors 613 
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of the hypothetical AOPs are the human AO, which is decreased motor function in children. In 614 
rodents in vivo, hypoactivity is observed in offspring when treated with MDMA postnatally. This 615 
AO in animals is closest to the human AO observed in the one epidemiological study. Based on 616 
the suggested early KE derived from the in vitro studies, we here suggest two hypothetical AOPs.  617 
The first one (Figure 5) is based on the observation that the model compound for this AOP, 618 
MDMA, is transported to the cytoplasm by serotonin transporters competing with 5HT uptake 619 
and inducing back-transport of 5HT out of the cell (Hasenhuetl et al., 2018). This mechanism 620 
produces first an increase in extracellular 5HT but finally leads to a depletion of 5HT as a result 621 
of a combined effect in other targets like inhibition of tryptophan hydroxylase, the rate-limiting 622 
enzyme for 5HT synthesis (Capela et al., 2009). These effects are described in adult brains 623 
(Capela et al., 2009), but experimental results reviewed in this article suggest that this 5HT 624 
depletion also takes place during neurodevelopment specially after neonatal exposure to 625 
MDMA and in particular the hippocampus. Depletion of serotonin concentrations during 626 
development by the model compound PCPA leads to locomotor deficits (Vinay et al., 2005) 627 
linking this KE2 to an AO in animals. Supporting this link, neonatal intraventricular injections of 628 
the selective serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) leading to serotonin 629 
depletion in frontal cortex, hippocampus and striatum, also produced a reduction in locomotor 630 
activity in rats (Rok-Bujko et al., 2012). Serotonin deficiency during development causes 631 
alterations in neuroanatomical structures (KE4), one of them disturbing the development of 632 
brain stem projections into the lumbar enlargement of the spinal cord, resulting in poorer motor 633 
control (Vinay et al., 2005). If these disturbances are the reason for the AO seen after MDMA 634 
exposure in humans (KE4R to the human AO) is currently unknown. Over all, this is a hypothetical 635 
AOP with a high amount of uncertainty. 636 
The second hypothetical AOP (Figure 5) involves the dopaminergic system and has even less 637 
supportive evidence than the first one. Here, altered DA receptor signaling during development 638 
alters amongst others tangential migration of GABAergic neurons possibly resulting in 639 
inappropriate neuronal excitation-inhibition balance in cortex, which could change motor 640 
activity. For example, the hyperdopaminergic DA transporter knockout mouse displays the 641 
behavioural phenotype of hyperactivity (Money and Stanwood, 2013). Much more data is 642 
needed to fill the gaps of this hypothetical AOP. 643 
 644 
 645 
Figure 5. Hypothetical AOPs proposed from the data collection of this systematic review. (A) This AOP 646 
describes the interference of a compound with the serotonin transporter and enzyme synthesis during 647 
brain development leading to decreased motor functions in children. (B) The second AOP describes 648 
alteration of DA receptor signaling during development leading to a cortical imbalance of excitatory and 649 




This exercise revealed that there are huge data gaps in the understanding of basic biology as 652 
well as MDMA toxicology. There is no consistent evidence that links the adverse effects of 653 
MDMA across the different levels of organisations: cellular, organ and organism. From the AO 654 
point of view, postnatal exposure in rodents seems to reflect MDMA effects in exposed humans 655 
better than prenatal exposure. The reason for this and for the opposite effects seen after pre- 656 
and postnatal exposure in rodents are not known. Research needs for fully understanding how 657 
MDMA causes which adverse effects in humans should include further mechanistic in vitro 658 
studies, preferably in human developing brain cells, e.g. human induced pluripotent stem cell 659 
(hiPSC)-derived neural cells, or in alternative whole organisms, which allow the combination of 660 
mechanistic evaluations with behavioural assessments. Moreover, follow-up studies of 661 
prenatally exposed children is important because the transmitter systems altered by MDMA, i.e. 662 
the NE, DA and serotonergic systems, also determine psychiatric diseases later in life. Clearly 663 
more data are needed that shed light on the mechanisms and consequences of prenatal MDMA 664 






Table 8. Summary of DNT studies of MDMA in vitro. 
Reference Species Cell type Age at 
cell 
isolation 
Exposure scheme Exposure 
duration 















ICC 0,75-750 µM 0,75 µM 




Mouse Embryonic stem cells 
(Royan B1)  
- During EB formation 
until 10 DIV 
240 h General neuronal endpoint MAP2 expression RT-qPCR 0.1-1000 µM 10 µM 
      General neuronal endpoint Neuronal morphology ICC 0.1-1000 µM IC50= 50µM 
    Starting at 4 DIV 
(after EB formation) 
96 h General neuronal endpoint MAP2 expression RT-qPCR 0.1-1000 µM - 
     96 h General neuronal endpoint Neuronal morphology ICC 0.1-1000 µM IC50= 120µM 
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